Creatine is a molecule that is produced in the body, where it exists additionally in the form of creatine phosphate. Creatine is also found in foods, mostly meat, eggs and fish.
Creatine confers a variety of health benefits, including neuroprotective and cardioprotective properties. It also improves power output and is often used by athletes to increase high-intensity exercise capacity and lean body mass.
Creatine’s main action in the body is storing high-energy phosphate groups in the form of phosphocreatine. During periods of stress, phosphocreatine releases energy to aid cellular function. This is what causes strength increases after creatine supplementation, but this action can also aid the brain, bones, muscles and liver. Most of the benefits of creatine are provided through this mechanism.
Side effects of creatine include stomach cramping, which can occur if creatine is supplemented with insufficient water, and diarrhea, if too much creatine is supplemented at once.
Follow this Page for updates
a-methylguanidinoacetic acid, creatine monohydrate, creatine 2-oxopropanoate
Creatinine (metabolite), Cyclocreatine (Analogue), Creatinol O-Phosphate (Analogue)
High doses of creatine acutely can cause gastrointestinal upset, resulting in slight nausea and diarrhea; doses should be spread out over the day and taken with meals if this occurs.Examine.com Medical Disclaimer
Creatine monohydrate can be supplemented through a loading protocol. To start loading, take 0.3g/kg bodyweight for 5-7 days, then follow with a minimum daily 0.03g/kg dose either for three weeks (if cycling) or indefinitely without requiring another load.
For the average person, these doses tend to result in 20g taken during the loading phase and around 2g taken daily henceforth although many users take 5g daily due to the low price of creatine and possibly more benefits; higher doses may be prudent for those with a high amount of muscle mass and high activity levels.
There are many different forms of creatine available on the market, but creatine monohydrate is the cheapest and most effective form of creatine. Micronized creatine is easier to dissolve in water, which may make it easier to supplement.
Creatine is usually taken daily.
Side-effects related to dosing are nausea, cramping, and diarrhea. These occur either when creatine is not taken with liquids, when too much of a dose is taken acutely, and can be attenuated by taking creatine with food.
I honestly see no reason why somebody shouldn't supplement creatine, nor do I see any logical basis for the seeming 'fear' of this compound in society.
It's safe, it's healthy, it's cheap, and for most people, it just works. Get some Creatine Monohydrate, take 5g a day, and you're good to go.
If humans didn't make any in the body, this thing would be a vitamin. There do exist deficiency symptoms that result in mental retardation. They're rare, but they pretty much establish the importance of this molecule as a vitamin-like compound.
Creatine is quite well-studied, and seems safe and effective in enhancing some aspects of performance.
5g a day of the cheap monohydrate powder (no need for anything fancy) seems great for anyone who's looking to increase power output.
In short: if you do something like sprinting or strength training, it's probably worth taking.
The Human Effect Matrix looks at human studies (excluding animal/petri-dish studies) to tell you what effect Creatine has in your body, and how strong these effects are.
|Grade||Level of Evidence|
|A||Robust research conducted with repeated double blind clinical trials|
|B||Multiple studies where at least two are double-blind and placebo controlled|
|C||Single double blind study or multiple cohort studies|
|D||Uncontrolled or observational studies only|
|Level of Evidence ||Effect||Change||Magnitude of Effect Size ||Scientific Consensus||Comments|
Creatine is the reference compound for power improvement, with numbers from one meta-analysis to assess potency being "Able to increase a 12% improvement in strength to... show
|A||Muscle Creatine Content|
Creatine supplementation is the reference compound for increasing muscular creatine levels; there is variability in this increase, however, with some nonresponders.
Does appear to have inherent lean mass building properties, but a large amount of research is confounded with water weight gains (difficult to assess potency).
Appears to have a large effect on increasing overall weight due to water retention in persons who respond to creatine supplementation. Degree of increase is variable.
Appears to be quite notable due to the increase in water weight in skeletal muscle tissue following creatine supplementation.
|A||Anaerobic Running Capacity|
Appears to increase anaerobic cardiovascular capacity, not to a remarkable degree however.
On the whole, there is no reliable improvement in swimming performance with creatine supplementation. In the instances where it could be beneficial, a loading period (no... show
Creatine supplementation usually increases serum creatinine levels during the loading phase (usually not maintenance) since creatinine is the breakdown product of creatine;... show
A minor reduction, nothing to a remarkable degree.
While creatine is reliable at increasing lean mass (acutely water, more prolonged supplementation is muscle), it does not appear to significantly modify fat mass at all.
In otherwise healthy persons given creatine supplementation, there is no significant beneficial nor negative influence on kidney function.
Degree of testosterone spike is not overly notable, although it appears to be present
The influence of creatine on well being and general happiness is usually dependent on it treating a disease state; there does not appear to be a per se benefit to well being.
No inherent benefit to omnivore cognition appears apparent, but it may benefit cognition in the sleep deprived.
Improvements in VO2 max are not wholly reliable, and appear to be low in magnitude.
Small degree of fatigue reduction during exercise, but appears unreliable.
|B||Exercise Capacity (with Heart Conditions)|
Although there may be a small reduction of power output (typical of creatine), the main parameter of interest (cardiorespiratory output) is mostly unaffected by creatine... show
Not overly protective, but there appears to be a degree of protection.
In otherwise healthy males given creatine supplementation, overall levels of cholesterol are unaffected.
Insufficient evidence to support a role of creatine in increasing IGF-1
|B||Treatment of COPD|
The main parameters of concern when treating COPD (lung and heart function, cardiovascular exercise performance) are not affected with creatine supplementation.
|B||Exercise Capacity in COPD|
The main parameter of interest with exercise in COPD (cardiovascular capacity and aerobic exercise) is wholly unaffected with supplementation, although power output still... show
Either in healthy persons or in disease states characterized by impaired lung function, creatine supplementation does not modify the strength of exhalations or lung power.
Does not appear to significantly influence blood pressure.
The spike in blood glucose following a meal may be reduced in the range of 11-22% following creatine supplementation, with no apparent influence on fasting blood glucose.
Fasting insulin concentrations are not affected with creatine supplementation.
Cortisol changes associated with sleep deprivation are not affected with supplementation of creatine.
Does not appear to confer any apparent benefit to prolonged cardiovascular exercise.
In the fatigue experienced by children subject to tramautic brain injury, frequency of fatigue is reduced from 90% down to 10% with 400mg/kg oral ingestion daily. Fatigue... show
|B||Bone Mineral Density|
Limited evidence in favor of improvements in bone mineral density with creatine supplementation
No known influence on circulating liver enzymes, suggesting no liver toxicity in humans.
|B||Treatment of Amyotrophic lateral sclerosis (ALS)|
Short term usage may increase power output like usual, but prolonged supplementation of creatine has failed to alter the deterioration of muscle and lung function. While... show
In otherwise healthy persons given creatine supplementation, there is no significant beneficial nor negative influence on kidney function.
On studies in swimmers, there is no apparent reduction or increase in lactate after sprinting exercises.
There is no known influence of creatine supplementation on heart rate.
|B||Treatment of Myotonic Dystrophy|
It seems that preliminary evidence supports a beneficial role for Myotonic Dystrophy type II (DM2) to a minor to moderate degree, and there is either a mild or no benefit to DM1.
Improvements in VO2 max are not wholly reliable, and appear to be low in magnitude.
Appears to reduce exercise-induced DNA damage; practical relevance unknown but potentially promising for cancer prevention.
Lack of comparator prevents proper assessment of potency; practical relevance unknown
No significant influence on protein losses in the urine (proteinuria)
|C||Symptoms of Osteoarthritis|
Appeared to increase functionality, although not to a remarkable degree.
Creatine supplementation does not appear to significantly alter food intake (unconsciously).
Appears to be reliable in increasing cognition in vegetarians, but is based on limited evidence and not yet compared to a reference drug.
Appears to be somewhat effective in diabetics for improving glycemic control.
An increase in DHT has been noted in one study independent of an increase in testosterone, requires replication due to some potential issues (location of study, lack of... show
|C||Symptoms of Duchenne Muscular Dystrophy|
There appears to be a mild therapeutic effect of creatine supplementation (2-5g) to boys with DMD, mostly related to an improvement in handgrip strength and body composition... show
|C||Skeletal Muscle Atrophy|
One study noted a prevention of lean mass loss (did not distinguish between water and muscle), while the study measuring muscle mass specifically failed to find a protective... show
Minor reductions in uric acid.
Notable due to seeming to be related to serotonin and augmenting SSRI therapy, and appears to have a gender difference (efficacy in females) which needs to be explored more.
Insufficient evidence to support a role in schizophrenia
There do not appear to be any alterations in insulin sensitivity associated with creatine supplementation.
|C||Symptoms of Sleep Deprivation|
The cognitive dysfunction associated with prolonged sleep deprivation can be attenuated with creatine loading prior to said sleep deprivation, but this is to a small degree.
Supplementation of creatine does not influence short term recall during sleep deprivation
|C||Treatment of Parkinsons|
Insufficient evidence to support an improvement in cognitive symptoms of Parkinson's (may aid physical capacities)
|C||Body Cell Mass|
Limited evidence measuring cell volume, but creatine may increase the cell mass.
|C||Satellite Cell Recruitment|
Unable to assess potency of this change based on comparisons to reference drugs.
Appears to induce myonuclei proliferation, unknown potency relative to other agents.
|C||Functionality in Elderly or Injured|
Possibly an effect, but the less reliable effects of creatine in the older population (which seem to respond less) seems to manifest here.
Attention during sleep deprivation is not affected with creatine supplementation
No significant alterations in plasma adrenaline are seen with creatine supplementation during sleep deprivation.
No significant alterations in plasma noradrenaline are seen with creatine supplementation during sleep deprivation.
No significant alterations in plasma dopamine are seen with creatine supplementation during sleep deprivation.
Creatine is able to suppress growth hormone secretion during exercise when loaded (up to 35%) and to a lesser degree during maintenance (5% or less) while creatine at rest... show
Swimming training volume is unaffected by creatine supplementation.
|C||Treatment of Huntington's Disease|
Insufficient evidence to support a rehabilitative role of creatine.
Decrease in homocysteine (biomarker of inflammatory cardiovascular disease) was present, but not to a remarkable magnitude
Appears to reduce exercise-induced DNA damage; practical relevance unknown but potentially promising for cancer prevention.
Degree of improvement is somewhat more potent than other supplemental options, and may be related to the improvements in glycemic control seen with creatine.
Notable as it may be a reference compound (17% reduction in circulating Myostatin) although it is uncertain what practical relevance this holds.
The insulin secretion in response to a test meal does not appear to be altered with creatine supplementation.
|C||Injury Rehabilitation Rate|
|C||Symptoms of McArdles Disease|
The two trials conducted at this moment in time have shown differing effects, and the reason for these differing effects are currently not known.
|C||Symptoms of Mitochondrial Cytopathies|
|C||Anti-Oxidant Enzyme Profile|
Increases in alertness tend to be during sleep deprivation or stress, rather than outright increases in alertness. Not overly potent
Lack of comparator prevents assessment of potency.
|D||Range of Motion|
One study noting a reduction in range of motion with creatine supplementation, needs to be replicated.
|D||Symptoms of Cystic Fibrosis|
Although there is an increase in well being and muscular strength in youth given creatine supplementation, the main parameters under investigation (lung and chest symptoms)... show
Dizziness as a side-effect of traumatic brain injury is halved in frequency with daily supplementation of 400mg/kg creatine intake.
|D||Treatment of Headaches|
In children and adolescents subject to traumatic brain injury who then received 400mg/kg creatine supplementation, headache frequency as a side effect is reduced from around... show
The influence of creatine on well being and general happiness is usually dependent on it treating a disease state; there does not appear to be a per se benefit to well being.
Creatine is a small peptide structure (composed of amino acids) and is made up of L-Arginine, Glycine, and L-Methionine. It is found in the cardiac and muscle tissue of animals and humans in high levels, but is also present in almost all mammalian cells, and acts as a reservoir for phosphate.
Cells use a molecule known as adenosine triphosphate (ATP) for energy, which, upon its own exhaustion, gets converted into ADP or AMP. While the protein known as adenosine monophosphate kinase (AMPK) tends to promote AMP to ADP conversions, the form of creatine that acts as the reservoir (creatine phosphate or phosphocreatine) regenerates ADP to ATP so it can be used once again to fuel metabolic processes.
Supplementation of creatine is thought to increase the overall pool of creatine and phosphocreatine in a cell. Secondary to that, the regeneration of ATP from ADP is accelerated. Most benefits of creatine supplementation are thought to be secondary to either a promotion of energy production or preventing ATP from getting too low in a cell.
Creatine is a small peptide which serves as a reservoir for phosphate, and it acts by regenerating the main cellular currency known as ATP. Supplementation of creatine or an increase in dietary creatine intake is thought to promote the regeneration of ATP and increase cellular energy stores
Conversely, some meats are poor sources of creatine, including:
In regard to meat products, creatine is accumulated in the same organs that a human should expect creatine to accumulate in after supplementation. Organs with a high creatine content include the heart and skeletal muscle
Other compounds that possess creatine include:
Dairy products have a minimal creatine content, but beyond meat products they are the only other significant source of creatine
According to the NHANES III survey of American adults, the daily (average) consumption of creatine from food sources is about 7.9mmol and 5mmol for men and women, respectively, in the 19-39 year age group. This is below the "2g consumed via the diet" estimate that many studies reference. Specifically, these values correlate to 1.08g and 0.64g of creatine, respectively.
Although consumption of creatine in food reduces the uptake rate due to being associated with chyme, there are no differences in total bioavailability.
Creatine is a peptide compound, made of the two amino acids known as glycine and Arginine that combine to form the backbone known as guanidinoacetate. Creatine's skeleton structure is depicted below.
During cooking, creatine degrades into methylamine, which can then be incorporated into the toxic substance N-methylacrylamide by binding to acrylic acid and acrylamides (produced from carnosine and aspartic acid cooking). The intermediates, acrylamides and acrylic acid, are dependent on the cooking temperature and the presence of a reducing sugar, such as glycogen.
Creatine may also be converted to the biologically inactive creatinine through the removal of a water molecule. Approximately 30% of meat-bound creatine can be lost in exudate or degraded into creatinine when cooking to medium-well.
Creatine is an energy intermediate. It exists in cells to donate a phosphate (energy) group to adenosine diphosphate (ADP) molecules to turn them into adenosine triphosphate (ATP). ATP can be seen as the cellular energy "currency," and is the molecule that is synthesized after the breakdown of any energy substrate (carbohydrates, fatty acids, ketones) for metabolizable energy. Meanwhile, carbohydrates are able to provide quick energy in an anaerobic environment (high-intensity exercise), and fats are mobilized to provide energy during periods of high oxygen availability at a slower rate (low-intensity exercise or rest). In both cases, available creatine is used to rapidly replenish ATP.
Creatine storage in the body is limited. Over 95% of the body's creatine is stored in muscle at a maximum cellular concentration of 30uM. Creatine storage capacity increases with increasing muscle mass, and if were are to assume a 70kg male with an average physique, whole-body creatine stores are about 120g. In contrast to creatine, one can accumulate dozens of pounds of body fat, and glycogen is only stored in the liver, brain, and muscles.
Creatine is an energy substrate. Creatine, glucose (carbohydrates), and fatty acids (dietary fat) all serve to replenish ATP, which is the energy "currency" of the cell. Creatine replenishes ATP at a faster rate than either glucose or fatty acids, and is the first line of cellular ATP replenishment. Stores are limited, however, and glucose or fatty acids quickly take over energy replenishment. Creatine serves a vital role in the very first stages of energy replenishment, preventing a depletion of ATP.
Without supplementation, creatine is formed primarily in the liver, with minor contribution from the pancreas and kidneys. The two amino acids, glycine and Arginine, combine via the enzyme Arginine:Glycine amidinotransferase (AGAT) to form Ornithine and guanidoacetate. This is the first of two steps in creatine synthesis, and although rare, any deficiency of this enzyme can result in mild mental retardation and muscular weakness. AGAT is also the primary regulatory step, and an excess of dietary creatine can suppress activity of AGAT to reduce creatine synthesis by reducing AGAT mRNA levels, rather than competitive inhibition.
Guanidoacetate (made by AGAT) then receives a methyl donation from S-Adenosyl Methionine via the enzyme guanidinoacetate methyltransferase (GAMT) which produces S-adenosylhomocysteine (as a byproduct) and creatine. Deficiencies in GAMT are a bit more severe (although equally rare) relative to AGAT, resulting in severe mental retardation and autism-like symptoms.
For the most part, the above reactions occur in the liver, where most systemic creatine is synthesized, but the AGAT and GAMT enzymes have been located in lesser amounts in kidney and pancreatic tissue (the extra-hepatic synthesis locales). Neurons also possess the capability to create their own creatine.
A binding of two amino acids yields guanidoacetate, and then methylation of this molecule results in creatine. Two enzymes mediate this process, ornithine is formed, and S-adenylmethione (a methyl donor) is used up. Any error in the synthesis of creatine results in mental retardation.
As mentioned before, S-adenylmethionine must be converted to S-adenylhomocysteine in order for guanidoacetate to convert into creatine, during a process known as methylation. It has been suggested that the production of creatine accounts for up to 40% of the S-adenylmethionine used in the body for methylation processes.
Creatine supplementation alleviates the intrinsic burden of producing creatine. Supplementation reduces the expected increase in homocysteine after intense exercise and may be a reason why creatine is seen as cardioprotective around the time of exercise.
After supplementation of creatine monohydrate (loading phase, followed by 19 weeks maintenance), creatine precursors are decreased by up to 50% (loading) or 30% (maintenance), which suggests a decrease in endogenous creatine synthesis during supplementation. This appears to occur through creatine's own positive feedback and suppression of the l-arginine:glycine amidinotransferase enzyme, the rate-limiting step in creatine synthesis, as levels of intermediates before this stage are typically elevated by up to 75%.
A suppression of creatine synthesis is seen when enough creatine is supplemented to cover the vital needs (approximately 4g daily, 2g of which would have been synthesized). This suppression may be beneficial to health, due to the inherent costs associated with creatine synthesis.
Creatine is stored in the body in the form of creatine and as creatine phosphate, otherwise known as phosphocreatine, which is the creatine molecule bound to a phosphate group. Creatine phosphate is thought to maintain the ATP/ADP ratio by acting as a phosphorus reservoir. The more ATP a muscle has relative to ADP, the higher its contractility is, and thus its potential strength output in vivo. This pro-energetic mechanism also affects nearly all body systems, not just skeletan muscle.  During periods of rest and anabolism, creatine can gain a phosphate group through the creatine-kinase enzyme pathway, up to a cellular concentration of 30uM to be later used for quick ATP resupply when needed. Creatine kinase enzymes (of which there are numerous isozymes) exist in both the mitochondria and the cytosol of the cell. The four isozymes of creatine kinase include the Muscle Creatine Kinase (MCK), present in contractile muscle and cardiac muscle, and the Brain Creatine Kinase (BCK), expressed in neuron and glial cells and some other non-muscle cells. These two Creatine Kinases are met with Sarcolemmic Mitochondrial Creatine Kinase (sMitCK), expressed alongside MCK, and the ubiquitous Mitochondrial Creatine Kinase (uMitCK), which is expressed alongside BCK everywhere else.
Creatine and creatine phosphate form a couplet in cells, which sequesters phosphate groups, which are then donated to ADP to quickly reform it into the main energy molecule known as ATP. This donation is faster than any other process in a cell for replenishing energy, and higher cellular creatine levels result in more phosphate donation and subsequent energy replenishment.
Increasing cellular survival (by preventing ATP depletion, cells survive longer) against hypoxia, oxidative damage, and some toxins against neurons and skeletal muscle cells is a mechanism of creatine supplementation mediated via creatine-kinase. This has also been shown to have efficacy against toxin-induced seizures.
Expressing the creatine-kinase enzyme in cells that do not normally express it (and thus enabling these cells to use creatine) exerts protective effects, while inhibiting this enzyme reduces survival rates.
Creatine and phosphocreatine surplus within a cell serves as an energy reservoir that can protect cells under periods of acute stress, and may enhance cell survival secondary to its bioenergetic effects.
When looking at race interactions, black people appear to have higher activity of the creatine kinase system when compared to both white and hispanic people, with hispanic people having greater levels than whites. The differences between races are more pronounced in men.
When splitting a sample into exercisers and non-exercisers, it appears that exercise as a pre-requisite precedes a higher range of activity. Those who are inactive tend to be on the lower end of creatine kinase activity and relatively clustered in magnitude while exercises generally increases activity, but introduces a larger range of possible activity.
Men appear to have higher active Creatine-Kinase systems, and racial differences favor Blacks over Hispanics over Whites for the activity of the Creatine-Kinase system. This system is more variable in men (independent of supplementation). Exercise may increase the activity of the Creatine-Kinase system independent of supplementation
Creatine is also a neurological nutrient. Individuals who cannot produce endogenous creatine suffer from a form of mental retardation with autistic-like symptoms due to deficiencies in the enzymes of creatine synthesis (AGAT or GAMT).
The main storage area of creatine in the human body is the skeletal (contractile) muscle, which holds true for other animals. Therefore, consumption of skeletal muscle (meat products) is the main human dietary source of creatine. Since vegetarians and vegans lack the main source of dietary creatine intake, which has been estimated to supply half of the daily requirements of creatine in normal persons, both vegetarians and vegans have been reported to have lower levels of creatine. This also applies to other meat-exclusive nutrients, such as L-Carnitine.
Due to this relative deficiency-state in vegetarians and vegans, some aspects of creatine supplementation are seen as more akin to normalizing a deficiency, rather than providing the benefits of supplementation. In young vegetarians, but not omnivores, creatine supplementation can enhance cognition. The increased gain in lean mass may be more significant in vegetarians, relative to omnivores. Supplementation of creatine in vegetarians appears to normalize the gap in storage between vegetarians and omnivores. This is possibly related to a correlation seen in survey research where vegetarianism and veganism appear to be more commonly affected by some mental disorders like anxiety and depression.
The importance of supplemental creatine is elevated in vegetarian and vegan diets due to the elimination of creatine's main dietary sources.
Creatine monohydrate is the most common form of creatine, and if not otherwise mentioned is the default form of creatine used in most studies on creatine. It has fairly decent intestinal absorption (covered more in depth in the pharmacology section) and is the standard form or 'reference' form of creatine, which all other variants are pitted against.
This basic form of creatine comes in two forms, one of which involves the removal of the monohydrate (which results in creatine anhydrous) that converts to creatine monohydrate in an aqueous environment, but due to the exclusion of the monohydrate it is 100% creatine by weight despite creatine monohydrate being 88% creatine by weight (as the monohydrate is 12%). This allows more creatine to be present in a concentrated formula, like capsules.
Creatine monohydrate can also be micronized (commonly sold as 'Micronized Creatine') which is a mechanical process to reduce particulate size and increase the water solubility of creatine. In regards to supplementation, it is equivalent to creatine monohydrate.
Creatine is most commonly found in the basic form of creatine monohydrate, which is the standard form and usually recommended due to the low price. It can also be micronized to improve water solubility or the monohydrate can be temporarily removed to concentrate creatine in a small volume supplement. Neither alteration changes the properties of creatine
Creatine hydrochloride (Creatine HCl) is a form of creatine where the molecule is bound to a hydrochloric acid moiety. It is claimed to require a lower dosage than creatine monohydrate, although this claim has not been tested.
Creatine hydrochloride likely lyses into free creatine and free hydrochloric acid when reaching the stomach, which would mean it is approximately bioequivalent to creatine monohydrate.
Creatine HCl is touted to require a lower dosage, but this is currently not proven through studies and seems logically very unlikely, since the stomach has an abundance of HCl anyway and creatine will freely dissociate with HCl in the stomach, resulting in the same thing creatine monohydrate does, free creatine.
Liquid creatine has been shown to be less effective than creatine monohydrate. This reduced effect is due to the passive breakdown of creatine over a period of days into creatinine, which occurs when it is suspended in solution. This breakdown is not an issue for at-home use when creatine is added to shakes, but it is a concern from a manufacturing perspective in regards to shelf-life before use.
Liquid creatine is ineffective as a creatine supplement due to it degrading in liquids, which shouldn't normally be an issue if you're preparing a creatine powder in your own house, since it takes a few days to occur, but it is a problem from the manufacturing side of things
Buffered Creatine (Kre-Alkylyn as brand name) is touted to enhance the effects of creatine monohydrate due to a higher pH level, which enables better translocation across the cytoplasmic membrane and more accumulation in muscle tissues.
This claim has not been demonstrated at this time, and a recent comparative study of buffered creatine against basic creatine monohydrate found no significant differences between the two in 36 resistance trained individuals, in regards to the effects or the accumulation of creatine in muscle tissue. There were no significant differences in the amount of adverse side-effects reported.
'Buffered' creatine (Kre-Alkylyn) is suggested to be a better absorbed form of creatine supplementation, but it can be rapidly neutralized in the stomach if not in an enteric coating. Even if it is enteric coated, it does not have support for its efficacy above creatine monohydrate
Creatine ethyl ester increases muscle levels of creatine to a lesser degree than creatine monohydrate. It may also result in higher serum creatinine levels due to creatine ethyl ester being converted into creatinine via non-enzymatic means in an environment similar to the digestive tract. At equal doses to creatine monohydrate, ethyl ester has failed to increase water weight after 28 days of administration (indicative of muscle deposition rates of creatine, which are seemingly absent with ethyl ester).
Creatine ethyl ester is more a pronutrient for creatinine rather than creatine, and was originally created in an attempt to bypass the creatine transporter. It is currently being studied for its potential as treatment for situations in which there is a lack of creatine transporters (alongside cyclocreatine as another possible example). Its efficacy may rely on intravenous administration, however.
Direct studies on creatine ethyl ester show it to be less effective than creatine monohydrate, on par with a placebo.
Creatine ethyl ester is 82.4% creatine by weight, and thus would provide 8.24g of active creatine for a dosage of 10 grams.
Creatine ethyl ether is likely ineffective as a variant of creatine since, despite it being able to passively diffuse through the cell membrane in vitro, it degrades into creatinine too rapidly in the intestines
Magnesium chelated creatine typically exerts the same ergogenic effects as creatine monohydrate at low doses. It was made because carbohydrates tend to beneficially influence creatine metabolism and magnesium is also implicated in carbohydrate metabolism and creatine metabolism. Magnesium chelated creatine may be useful for increasing muscle strength output in a similar potency to creatine monohydrate, but without the water weight gain (noted differences, but statistically insignificant).
Creatine magnesium chelate has some limited evidence for it being better than creatine monohydrate, but this has not been investigated further
Creatine Nitrate is a form of creatine where a Nitrate (NO3) moiety is supposedly bound to the creatine molecule, which has been demonstrated to enhance solubility in water by approximately 10-fold with the pH of 2.5 or 7.5 not significantly affecting the solubility. Beyond increased solubility, no other studies have been conducted using creatine nitrate.
Creatine nitrate is a highly water soluble form of creatine, and while it is theoretically possible that this possesses benefits of both creatine and nitrate, this has not been investigated
Creatine Citrate is creatine bound to citric acid, or citrate. Creatine Citrate does not differ greatly from monohydrate in regards to absorption or kinetics. Note that creatine citrate is more water-soluble than monohydrate,, but creatine absorption is generally not limited by solubility. The increased water solubility may play a factor in palatability.
Creatine Malate is the creatine molecule bound to malic acid. There might be some ergogenic benefits of malic acid on its own but this has not been investigated in conjunction with creatine. Malic acid/Malate also confers a sour taste and may negate the sensation of bitterness, common among some supplements.
Creatine citrate and creatine malate are variants of creatine, supplementation of which has increased water solubility and may have altered sensory (taste) properties due to its sour stimuli
Creatine pyruvate (also known as Creatine 2-oxopropanoate), in an isomolar dose relative to creatine monohydrate, produces higher plasma levels of creatine (peak and AUC) yet has no discernible differences in absorption or excretion values. The same study noted increased performance from creatine pyruvate at low (4.4g creatine equivalence) doses relative to citrate and monohydrate, possibly due to the pyruvate group.
Creatine pyruvate is 60% creatine by weight.
Creatine pyruvate has once been noted to reach higher levels of plasma creatine relative to an isomolar dose of creatine monohydrate, but the lone study failed to note differences in absorption (not supporting the increased serum levels) and this has not been replicated
Creatine α-ketoglutarate is the creatine molecule bound to an alpha-ketoglutaric acid moiety. Little research has been done with creatine α-ketoglutarate 
Creatine α-ketoglutarate is 53.8% creatine by weight.
Creatine α-ketoglutarate is thought to be an enhanced form of creatine supplementation (similar to Arginine α-ketoglutarate, which has an increased rate of absorption) but this has not been investigated
Sodium creatine phosphate is 51.4% creatine by weight.
Sodium creatine phosphate appears to be about half creatine by weight, and it is not certain what this variant does
Polyethylene glycosylated creatine (PEG creatine) appears to be somewhat comparable to creatine monohydrate
Creatine Gluconate is a form of creatine supplementation where the creatine molecule is bound to a glucose molecule. It currently does not have any studies conducted on it.
Creatine gluconate is sort of a glycoside of creatine, and it is thought to be better absorbed when taken alongside food, since many other gluconate molecules, particular on minerals like Magnesium, are absorbed better with food. That being said, there are currently no studies on this particular variant
Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) is an analogue of creatine in a cyclic form, and synthetically made. It serves as a substrate for the creatine kinase enzyme system, serving as a creatine mimetic. Cyclocreatine may compete with creatine in the CK enzyme system to transfer phosphate groups to ADP, as coincubation of both can reduce cyclocreatine's anti-motility effects on some cancer cells.
The structure of Cyclocreatine is fairly flat (planar), which aids in passive diffusion across membranes. It has been used with success in an animal study, where mice suffered from a SLC6A8 (creatine transporter at the blood brain barrier) deficiency, which is not responsive to standard creatine supplementation. This study failed to report increases in creatine stores in the brain, but noted a reduction of mental retardation associated with increased cyclocreatine and phosphorylated cyclocreatine storages. As demonstrated by this animal study and previous ones, cyclocreatine is bioactive after oral ingestion and may merely be a creatine mimetic, able to phosphorylate ADP via the creatine kinase system.
This increased permeability is noted in glioma cells, where it exerts anti-cancer effects related to cell swelling and in other membranes, such as breast cancer cells and skeletal (contractile) muscle cells. The kinetics of cyclocreatine appear to be first-order, with a relative Vmax of 90, Km of 25mM and a KD of 1.2mM.
In regards to bioenergetics, phosphorylated cyclocreatine appears to have less affinity for the creatine kinase enzyme than phosphorylated creatine in donating the high energy phosphate group (about 160-fold less affinity) despite the process of receiving phosphorylation being similar. When fed to chickens, phosphorylated cyclocreatine can accumulate up to 60mM in skeletal muscle which suggests a sequestering of phosphate groups before reaching equilibrium. Cyclocreatine still has the capacity to donate phosphate, however, as beta-adrenergic stimulated skeletal muscle (which depletes ATP and glycogen) had an attenuation of glycogen depletion (indicative of preservation of ATP) with phosphocreatine.
When looking at kinetics, cyclocreatine appears to be passively diffused through membranes and not subject to the creatine transporter, which can be beneficial for cases where the creatine transporter is hindering goals (creatine non-response and SLG6A8 deficiency). It works similarly, as it can buffer ATP concentrations but its efficacy in otherwise healthy persons as a supplement is currently unknown
Creatine is known to cause cellular water retention, and this 'swelling' of a cell is known as a hypo-osmotic state, which is known to per se have biological consequences and is thought to be associated with less protein catabolism within the cell and an increased synthesis of DNA. An increase in cellular viability assessed via phase angle (measuring body cell mass) has been noted in humans during supplementation of creatine.
Glycogen synthesis is known to respond directly and positively to cellular swelling, since relative to the normal medium of 300 milliosmoles (300mOsm/kg), increasing the osmolarity (170mOsm/kg) increases glycogen synthesis by 75% yet reducing it (430mOsm/kg) hinders it by 31%. These changes were not due to alterations in glucose uptake, but are blocked by hindering the PI3K/mTOR signalling pathway. It was later noted that stress proteins of the MAPK class (p38 and JNK) as well as heat shock protein 27 (Hsp27) are activated in response to increasing osmolarity, and activation of MAPK signalling in skeletal muscle cells are known to induce myocyte differentiation and are known to interact with GSK3β to influence MEF2 siganlling, which can induce muscle cell growth.
The increase in cellular swelling (water retention within the cell) per se appears to have a positive influence on muscle cell growth, since the increase in swelling is met with the activation of stress response proteins of the MAPK class, which then influence muscle protein synthesis. These mechanisms do not involve the creatine kinase cycle
Inducing hypertonicity (a reduction in cellular swelling) is known to actually increase the mRNA of the creatine transporter, thought to be due to increasing cellular creatine uptake to normalize creatine levels. This has been noted in both muscle cells and endothelial cells, but is thought to apply to all cells.
This regulation of creatine uptake is similar to other osmolytic agents such as myo-Inositol or Taurine, which have their uptake into cells enhanced during periods of hypertonia in order to increase cellular swelling.
Cellular hydration status is tied into creatine influx and efflux in a cell by modulating the expression of the creatine transporter and thus cellular uptake. This is similar to other osmolytes in the human body
Phosphocreatine, the higher energy form of creatine, can associate with and protect cell membranes. This was first observed in Drosophilia, which do not express the creatine kinase enzyme (and cannot use creatine for energy purposes) yet still received cellular protection from creatine. Later, when using a research membrane mimicking the mitochondrial membrane (and later cytosolic), it was found that at biologically relevant concentrations of 10-30mM exerting concentration-dependent binding to the membrane, phosphocreatine was more effective than creatine in this regard, although both bound (as well as cyclocreatine and phosphorylated cyclocreatine) and the membranes appeared to be stabilized.
Cyclocreatine (an analogue of creatine) has been shown to protect microtubules in a cell and protect its structure, but it is not known whether these benefits can be expanded to creatine.
Due to the phosphate group, phosphocreatine can bind to cellular membranes. This seems to protect membranes, and exerts protective effects on the cell via direct structural support. This is not related to either hydration of a cell nor the creatine kinase system, but its relevance to the human body is also uncertain at this time
Creatine is involved indirectly in whole body methylation processes. This is due to creatine synthesis having a relatively large methyl cost, as the creatine precursor known as guanidinoacetate (GAA) requires a methyl donation from S-Adenosyl Methionine (SAMe) in order to produce creatine. This may require up to half of the methyl groups available in the human body.
Creatine supplementation will downregulate the body's own production of creatine by suppressing the enzyme which mediates the above conversion (Guanidinoacetate methyltransferase or GAMT), and because of this it is thought that SAMe gets backlogged and is more available for other processes that require it.
SAMe is the primary methyl donor in the human body, and supplements that preserve SAMe (such as Trimethylglycine; TMG) promote a variety of benefits in the human body, like a reduction in homocysteine and reduced risk of fatty liver. Creatine has been implicated in both reducing homocysteine and preventing fatty liver in rodents, thought to be secondary to preserving SAMe.
Creatine synthesis requires a large amount of S-adenosyl methionine (SAMe) to be used, and downregulating creatine synthesis (via supplementation) indirectly preserves SAMe levels in the body. This is thought to indirectly promote the benefits of SAMe supplementation by preserving its bodily concentrations, acting in a similar manner as TMG
Creatine supplementation may be able to enhance lifespan, secondary to increasing intracellular Carnosine stores. Carnosine is the metabolic compound formed from Beta-Alanine supplementation, and in senescence-accelerated (premature aging, SAMP8) animals creatine supplementation without any beta-alanine may increase cellular Carnosine storages. That being said, the aforemented SAMP8 study noted an increase in middle age, but not old age in the mice. A human study using 20g of creatine for one week in otherwise healthy persons failed to find an increase in intracellular carnosine stores.
Creatine been noted once to increase intracellular carnosine stores, which was thought to be antiaging, but this may not apply to oral ingestion of creatine due to it not being reliable and has not yet been detected in humans
In the stomach, creatine can degrade by about 13% due to the digestive hormone pepsin, as assessed by simulated digestion. Gastric digestion does not result in an increase of creatinine, but said increase of creatinine is noted with pancreatic buffer. There seems to be non-creatinine intermediates.
Stomach acid can degrade a small amount of creatinine, which does not appear to be too practically relevant, judging by the multitude of studies noting benefits with oral creatine monohydrate that are subject to the stomach
The specific mechanism of intestinal uptake of creatine is not clear, although human mRNA for gut transporters and the presence of rat jujenum transporters suggests that humans have them in the jujenum. The observation that creatine can be absorbed against a concentration gradient to a max ratio of 8:1 (8 times more creatine in the intestinal cell post absorption, relative to the lumen) supports transporter-mediated uptake, and the dependence on sodium and chloride implicate SLC6A8 (Creatine Transporter 1) as the mechanism.
In standard dosages (5-10g creatine monohydrate) the bioavailability of creatine in humans is ~99% although this value is subject to change with different conjugates (forms) of creatine and dosage. Coingestion of cyclocreatine (an analogue) can reduce uptake by about half and coincubation of Taurine, Choline, glycine, or Beta-Alanine had minimal attenuation of absorption, which are likely not practically relevant. The inhibition noted with cyclocreatine may be due to receptor saturation.
There is also evidence that increased ingestion of creatine leads to an increased fecal creatine value, suggesting that the intestinal uptake can be saturated.
Most likely, intestinal uptake is mediated by SLC6A8 or a close variant (a sodium chloride dependent transporter) and doesn't appear to be hindered by other common supplements, although too much creatine at one time (greater than 10g) can saturate the receptors and will 'waste' excess creatine
Assuming absolutely no supplementation and standard dietary intake, basal (fasted) creatine concentrations in humans are in the range of 100-200µM (0.1-0.2mM) which is lower than that observed in rats (140-600µM).
Under fasting and nonsupplemental conditions, concentrations of creatine in the human body are in the low micromolar range
After the ingestion of 5g creatine in otherwise healthy humans, serum levels of creatine were elevated from fasting levels (0.05-0.1mmol/L) to 0.6-0.8mmol/L, within one hour after consumption. The receptor follows Michaelis-Menten kinetics with a Vmax obtained at concentrations higher than 0.3-0.4mmol/L, with prolonged serum concentrations above this amount exerting most of its saturation within two days.
2.5 hours after the ingestion of a 20g bolus of creatine, serum levels can increase up to 2.17mmol/L.
Creatine in serum follows a dose-dependent relationship, with more oral creatine ingested causing more serum increases. The rate of accrual into muscle cells may be maximized at a serum concentration achievable with 5g of creatine supplementation
The Creatine Transporter is a sodium/chloride-dependent transporter; dependent on both sodium and chloride. It belongs to the Na+/Cl-dependent family of neurotransmitter transporters. On the muscle cells and most other cells, the isomer of the creatine transporter is known as SLC6A8 and since it is a sodium-dependent transporter, it is involved with sodium flux across the membrane. This isomer is coded by the gene present on Xq28 of the human chromosome and applies to most tissues, while the other gene capable of encoding for the Creatine Transporter, 16p11.1, creates transporters that are testicle exclusive. These two transporters share 98% homology.
The creatine transporter is the sole method for taking creatine from the blood up into a cell, and it is a sodium chloride dependent transporter in the SLC family, also known as SLC6A8
This transport appears to be more active during states of creatine deficiency in the muscle and more active at levels closer to baseline. Some creatine transporters may exist in the sarcolemma of the muscle, which indicates that they may abide by vesicle transport, similar to GLUT4 translocation. The study itself indicates that 'some internal staining is evident' when staining creatine transporters.
There are actually two 'bands' of creatine transporter that tend to not be differentiated between in past studies: a 55kDa band and a 70kDa band (73kDa in humans). The 73kDa band appears to be more numerous in humans, with no difference based on gender.
Creatine uptake into cells is wholly regulated by the Creatine Transporter, of which the most common isoform is SLC6A8. The creatine receptor is expressed on the cytoplasmic membrane, but may also be sequestered inside a muscle cell. It is regulated based on creatine status and other factors
In general, muscle content of creatine tends to be elevated to 15-20% above baseline (more than 20mM increase) in response to oral supplementation. People who get a sufficiently high influx of creatine are known as responders. A phenomena known as 'creatine nonresponse' occurs when people have less than a 10mM influx of creatine into muscle after prolonged supplementation. Quasi-responders (10-20mM increase) also exist. Nonresponse is thought to explain instances where people do not benefit from creatine supplementation in trials, since some trials that find no significant effect do find one when only investigating those with high creatine responsiveness. There are clear differences between those who respond and those who do not in regards to performance. People who are creatine responsive tend to be younger, have higher muscle mass and type II muscle fiber content, but this has no correlation with dietary protein intake.
Creatine non-response is when muscular loading of creatine is under a certain threshold (10mmol/L), while 'response' to creatine means having more muscular creatine loading (20mol/L or more), with a grey area in-between where some benefits are achieved but not as many as pure responders will experience. Response appears to be positively related to muscle mass and type II muscle fibers
Creatine is only taken up by its transporter, and alterations in this transporter are wholly causative of changes in creatine uptake. The transporter is regulated by mostly cytosolic (within a cell) factors as well as some external factors that act on their receptors or extracellular creatine itself. They are further divided into positive regulators (those that increase activity of the transporter) and negative regulators (those that suppress activity).
The creatine transporter (CrT) is positively regulated by proteins known to signify a cellular energy state, including the mammalion target of rapamycin (mTOR) which, after it is activated, stimulates SGK1 and SGK3 to act upon PIKfyve and subsequently PI(3,5)P2 to increase CrT activity. Beyond mTOR, SGK1 (which increases activity of the receptor via the above means) is stimulated by intracellular calcium and a lack of oxygen (ischemia), which is thought to explain how muscle contraction itself increases creatine uptake into a cell via increasing the transporter.
Stress-inducible Kinases (SGK1, SGK3) increase the activity of the creatine transporter, and these proteins are increased by any intracellular stress (such as a lack of oxygen or calcium release from inside the cell) and are also activated when a protein known as mTOR is activated in response to caloric excess or leucine signalling
Some other cytokines and hormones may increase the receptor activity. These include growth hormone (GH) which acts upon the growth hormone receptor (GHR) to stimulate c-Src which directly increases the activity of the CrT via phosphorylation. This is known to occur with the 55kDa version of c-Src but not the 70kDa version and requires CD59 alongside c-Src.
There is a nuclear receptor known as TIS1 (orphan receptor, since there are no known endogeouns targets at this time) which positively influences transcription of new creatine transporters and, in C2C12 myotubes, seems to be responsive to cAMP or adenyl cyclase stimulation from Forskolin (from Coleus forskohlii) with peak activation at 20µM.
Both growth hormone and TIS1 increase the activity of the creatine transporter in a manner different than the cellular stresses, since growth hormone directly activates it via another pathway (c-Src) while TIS1 is involved in making more of the receptors overall. TIS1 seems to respond to intracellular cAMP levels
Finally, starvation (nutrient deprivation for four days) appears to increase activity of the creatine transporter secondary to decreasing serine phosphorylation (SGK target) with no influence on tyrosine phosphorylation (c-Src target), and the increase in creatine influx does not necessarily mean more phosphocreatine because of the initially depleted cellular energy state.
Starvation increases creatine uptake into cells, but due to no appreciable conversion into phosphocreatine, this method of increasing creatine uptake may be useless (if not counterproductive since prolonged starvation was required) for the benefits of supplementation
In regards to practical interventions, physical exercise prior to creatine loading (to a level which is enough to sufficiently deplete glycogen in the exercised tissue) has been noted to increase muscular creatine levels to 37-46% regardless of whether the tissue was exercised or not. This is a larger increase than usually seen with a loading protocol (usually in the 20-25% range) and it is thought to be because exercise itself increases creatine uptake into muscle, although the other study to note this found a 68% greater creatine uptake in the exercised limb relative to an unexercised (14%), which was of lower magnitude than the aforementioned study.
Exercise itself appears to stimulate creatine uptake into muscle, and it is possible that the more metabolically intense the exercise is on the tissue level, the more creatine uptake is increased
Negative regulators of the creatine transporter (CrT) are those that, when activated, reduce the activity of the CrT and the overall creatine uptake. Similar to the natural antagonism of AMPK and mTOR it seems that the increase in activity of the CrT seen with mTOR is met with a suppression of activity when AMPK is activated and can be replicated by directly inhibiting mTOR. This appears to be indirect, since AMPK stimulates TSC2 to suppress mTOR and merely takes away the positive regulation of the CrT from mTOR. Although indirect, activation of AMPK has been noted to reduce the Vmax of the CrT without altering creatine binding, and is involved in internalizing the receptors. This pathway seems to max out at around 30% suppression, with no combination of mTOR antagonists and AMPK inducers further suppressing creatine uptake.
AMPK activation is normally antagonistic to mTOR activation (due to signifying a cellular energy deficiency rather than surplus), and it seems that activation of AMPK will suppress mTOR activity (via TSC2) and prevent the upregulation from mTOR from occurring. While not technically a negative regulator, it seems like one by preventing a positive regulator from acting
Extracellular creatine (creatine outside of a cell) appears to influence creatine uptake into a cell. It seems that prolonged and excessive levels of creatine actually suppress uptake (a form of negative regulation to prevent excessive influx). This is thought to be due to the protein known as JAK2, which suppresses the rate of creatine uptake via the CrT without affecting creatine binding.
This protein (JAK2) is a regulatory protein involved in stabilizing the cellular membrane and controlling water concentrations in a cell (hypertonicity) and, similar to c-Src (a positive regulator), is induced by growth hormone when growth hormone acts upon its receptor. The growth hormone receptor seems to increase these two factors fairly independently (increasing c-Src does not require JAK2 and eliminating JAK2 does not impair c-Src production) and it is currently thought that when growth hormone signalling is switched from the c-Src/ERK pathway towards the JAK2/STAT pathway that whatever mediates this conversion also changes growth hormone's positive regulation into a negative regulation.
JAK2 (Janus-Activating Kinase 2) is a protein that suppresses the activity of the creatine receptor directly, and it is thought that JAK2 is merely acting downstream from the growth hormone receptor. While the growth hormone receptor normally causes an increase in activity of the CrT via c-Src, it appears to be able to shift signalling towards a suppressive pathway on an as-needed basis
Creatine is vital for proper neural functioning, and true creatine deficiency results in mental retardation. Deficiency can occur by either hindered synthesis (lack of enzymes to make creatine, can be treated with supplementation) or by a lack of transport into the brain (untreatable with standard creatine).
Entry into neural tissues in general is mediated by the secondary Creatine Transporter (CrT-2) known as SLC6A10 with an mRNA sequence of BC012355 and (CrT2) is the same transporter that is active in a male's testicles. It belongs to the family of SLC6 transports that act to move solutes across the membrane by coupling transport with sodium and chloride. Deletion of the gene at 16p11.2 (ie. a genetic flaw), which mediates both SLC6A8 and SLC6A10 production, can result in mental retardation in humans and is one of the causes of 'Creatine Deficiency Syndrome'. Blame cannot be placed on a lack of either transport, as both, as well as synthesis, are important neurally. The other cause of retardation is a lack of creatine synthesis, which can be reversed with creatine supplementation and dietary changes.
In regards to the blood brain barrier (BBB), which is a tightly woven mesh of non-fenestrated microcapillary endothelial cells (MCECs) that prevents passive diffusion of many water-soluble or large compounds into the brain, creatine can be taken into the brain via the SLC6A8 transporter whereas its precursor (guanidinoacetate, or GAA) only appears to enter this transporter during creatine deficiency. More creatine is taken up than creatine is effluxed, and more GAA is effluxed rather than taken up, suggesting creatine utilization in the brain from blood-borne sources is seen as the major source of neural creatine usage. However, 'capable of passage' differs from 'unregulated passage' and creatine appears to have tightly regulated entry into the brain in vivo. After injecting rats with a large dose of creatine, creatine levels increased and plateaued at 70uM above baseline levels (where baseline levels are about 10mM, this equates to an 0.7% increase when superloaded). These kinetics may be a reason for relatively lacklustre results of creatine supplementation on neural effects in creatine sufficient populations.
Creatine is vital for the functioning of the brain, which has mechanisms to take up creatine, as well as regulate its intake. Although the diet appears to be the major source of creatine (and thus lack of dietary intake could cause a non-clinical deficiency) excess levels of creatine do not appear to 'super-load' the brain similar to muscle tissue. Due to kinetics, creatine appears to be more 'preventative' or acts to restore a deficiency, in regards to the brain, as compared to its effects in muscle cells, where it can affect a person drastically and acutely
After the BBB, SLC6A8 is also expressed on neurons and oligodendrocytes, but it is relatively absent from astrocytes, including the astrocytic feet which line 98% of the BBB. Creatine can still be transported into astrocytes (as well as cerebellar granule cells) via SLC6A8, as incubation with an SLC6A8 inhibitor prevents accumulation in vitro. It seems to be less active in a whole brain model, relative to other brain cells.
Without supplementation, approximately 14.6mmol (2g) of creatinine, creatine's urinary metabolite, is lost on a daily basis in a standard 70kg male aged 20-39. The value is slightly lower in females and the elderly due to a presence of less muscle mass. This amount is seen as necessary to reach in either food or supplemental form to remain sufficient in creatine, and may be increased in people with higher than normal lean mass. Excretion rates on a daily basis are correlated with muscle mass, and the value of 2g a day is derived from the aforemention male population with about 120g creatine storage capacity. Specifically, the rate of daily creatine losses is about 1.6%-1.7%, and mean losses for women are approximately 80% that of men due to less average lean mass. For weight-matched elderly men (70kg, 70-79 years of age) the rate of loss of 7.8mmol/day is about half (53%) that of younger men.
Creatine appears to have a 'Daily Requirement' like a vitamin to maintain sufficient levels, at or around 2 grams assuming a 'normal' 70kg male body
Creatine levels in the blood tend to return to baseline (after a loading with or without the maintenance phase) after 28 days (4 weeks) without creatine supplementation. This number may vary slightly from one individual to another, and for some may exceed 30 days. Assuming an elimination rate of creatinine (creatine's metabolite) at 14.6mmol per day six weeks of cessation is nearing the upper limit for serum creatine to completely return to baseline.
Despite this decrease to baseline levels, muscle creatine and phosphocreatine levels may still be elevating and provide ergogenic effects.
Creatine can be elevated above baseline after supplementation of more than 2 grams, and depending on the degree of loading it may elevate bodily creatine stores for up to 30 days
Creatine retention (assessed by urinary analysis) tends to be very high on the first loading dose (65+/-11%) and declines during the loading phase (23+/-27%) likely due to increased muscular uptake during the initial stages, since (seen in vegetarians with lower initial muscular creatine stores) the retention is exacerbated initially but normalized during the last days of loading, due to normalization in creatine stores in muscle.
Coingestion of creatine with carbohydrates is known to increase glycogen accural in skeletal muscle (possibly resulting in larger muscular swelling) although the creatine content in muscles does not appear to be significantly increased.
Creatine maintenance is known as the period following loading (if the user chooses to load) and its duration may be indefinite. The goal of maintenance is to find the lowest daily dose required to optimize creatine stores and benefits of supplementation while reducing potential side-effects of loading (intestinal and gastric distress).
Sedentary people who undergo a loading period (2g of creatine daily for up to six weeks) are able to retain much of the creatine loading into skeletal muscles. Studies following this protocol note that (total free creatine) a 30.6% increase with loading is attenuated to 12.9%.
This partial preservation of creatine stores with 2g may be wholly irrelevant in athletes, as assessed by elite swimmers where 2g as maintenance (no loading phase) failed to alter creatine content in muscle whatsoever.
A maintenance phase of 2g daily appears to technically preserve creatine content in skeletal muscle of responders either inherently or after a loading phase, but in sedentary people or those with light activity, creatine content still progressively declines (although it still higher than baseline levels after six weeks) and glycogen increases seem to normalize. 2g may be wholly insufficient for athletes, and a 5g maintenance protocol may be more prudent
When looking collectively at the benefits accrued during loading and maintenance, it appears that changes in body mass are additive during this phase (increased during loading, further increased during maintenance).
Despite a possible decreasing creatine content in the muscles when maintenance is deemed suboptimal, the overall retention of weight and lean mass is merely additive over time. This is thought to be due to increases in skeletal muscle production (increase in body weight) compensating for the progressive declines in water and glycogen content (decreases in body weight)
When total free creatine declines (from 30.6% to 12.9%), the increase in glycogen seen during loading appears to normalize at a faster rate, so 2g of maintenance may not be sufficient to preserve glycogen.
Creatine at a concentration of 3mM does not appear to bind to nor modify the oxidant effects of iron in vitro.
In vitro, creatine (0.125mM or higher) can reduce excitotoxicity from glutamate, which is thought to be secondary to preserving intracellular creatine phosphate levels (ATP preserves membrane integrity) and is protective when either preloaded or added up to 2 hours after excitotoxicity. This protective effect extends to forms of excitotoxicity that circumvent the receptor (such as H2O2 incubation) which demonstrates that it works postsynaptically. This protective effect from glutamate-induced toxicity extends to glial cells and is additive with COX2 inhibition.
Creatine has been confirmed to be neuroprotective against excitotoxicity at a dietary level of 1% in rats (with no protective effect against AMPA or kainate receptors).
Creatine appears to be neuroprotective against glutamate-induced excitotoxicity, and appears to do so by providing a cellular buffer of energy
Creatine has been noted to increase the amplitude of signalling via NMDA receptors (0.5-5mM) and frequency (25mM only) although concentrations of 0.5-25mM reduced signalling intensity. This was accredited to creatine causing an increase in ligand binding of glutamate with an EC50 of 67µM and maximal activity at 1mM creatine (158+/-16% of baseline). Creatine appears to modulate the polyamine binding site of the NMDA receptor as it is abolished by arcaine and potentiated by spermidine. This binding site is known to modify NMDA receptor affinity.
Activation of NMDA receptors is known to stimulate Na+,K+-ATPase activity secondary to calcineurin, which which has been confirmed with creatine in hippocampal cells (0.1-1mM trended, but 10mM was significant), which is blocked by NMDA antagonists. This increase in Na+,K+-ATPase activity is also attenauted with activation of either PKC or PKA which are antagonistic with calcineurin.
Creatine appears to positively regulate the polyamine binding site of NMDA receptors, thereby increasing signalling through this receptor and the effects of agonists such as glutamate or D-Aspartic Acid. This is a potential mechanism for cognitive enhancement
In a prolonged study on mice, it was found that there was a two-fold upregulation of the transport SLC1A6, which mediates glutamate uptake into cells and depletes extracellular levels. This may underlie the reduction of brain glutamate levels by creatine seen in Huntington's Disease.
This is thought to be relevant since, in a study on subjects with amyotrophic lateral sclerosis (ALS), 15g of creatine daily was found to result in a significant reduction in combined glutamate and glutamine in the brain (not seen after 5-10g daily).
Creatine may also uptake glutamate into cells. How this influences signalling and neuroprotection is not yet clear
In isolated striatal cells (expressing creatine kinase), seven day incubation of 5mM creatine (maximal effective dose) appears to increase the density of GABAergic neurons and DARPP-32 (biomarker for spiny neurons) with only a minor overall trend for all cells and showed increased GABA uptake into these cells, as well as providing protection against oxygen and glucose deprivation.
One rat study that compared male and female rats and used a forced swim test (as a measure of serotonergic activity of anti-depressants) found that a sexual dimorphism existed, and females exerted a serotonin mediated anti-depressant response while male rats did not. It appears that these anti-depressive effects are mediated via the 5-HT1A subset of serotonin receptors, as the antidepressant effects can be abolished by 5-HT1A inhibitors.
In females, the combination of SSRIs (to increase serotonin levels in the synapse between neurons) and creatine shows promise in augmenting the anti-depressive effects of SSRI therapy. Another pilot study conducted on depression and females showed efficacy of creatine supplementation. The one study measuring male subjects noted an increase in mood and minimal anti-depressive effects, but it is not know whether this is due to gender differences or the model studies (Post-Traumatic Stress Disorder).
There is insufficient evidence to refute the notion that creatine supplementation only exerts anti-depressive effects in females. The evidence to suggest that creatine is an anti-depressant (via serotonergic mechanisms) appears to be much stronger for women than men
In humans, studies that investigate links between serotonin and creatine supplementation find that 21 trained males, given creatine via 22.8g creatine monohydrate (20g creatine equivalent) with 35g glucose, relative to a placebo of 160g glucose, was found to reduce the perception of fatigue in hot endurance training, possibly secondary to serotonergic modulation, specifically attentuating the increase of serotonin seen with exercise (normally seen to hinder exercise capacity in the heat) while possibly increasing dopaminergic activity (conversely seen to benefit activity in the heat).
Conversely, the suppression of serotonin spikes seen in males may enhance physical performance during periods when the body would normally overheat. The idea that this does not work in females cannot be refuted at this time
Creatine may preserve dopamine synthesis in the striatum of mice (while protecting against dopaminergic depletion) when fed to mice at 2% of the diet for one week prior to MPTP toxicity. This is possibly secondary to increasing tyrosine hydroxylase activity, the rate-limiting step of dopamine biosynthesis. Two percent creatine was as protective as 0.005% rofecoxib (a COX2 inhibitor), but the two were additive in their protective effects (highly synergistic in regards to DOPAC by normalizing it, but not synergistic in preserving HVA).
The neuroprotective effects of creatine appear to exist in regards to dopamine biosynthesis, and the suppression of dopamine synthesis seen with some neurological toxins appears to be partially attenuated with dietary intake of creatine. The protective effect is weak to moderate in animal research, but appears to be additive with anti-inflammatories
Oral intake of 5-15g of creatine daily, over 1-15 days, has failed to modify neural concentrations of choline in subjects with amyotrophic lateral sclerosis (ALS) despite brain creatine increasing at 15g.
Creatine, through its ability to act as an energy reserve, attenuates neuron death induced by the MPTP toxin that can produce Parkinson's Disease-like effects in research animals, reduces glutamate-induced excitotoxicity, attenuates rotenone-induced toxicity, L-DOPA induced dyskinesia, 3-nitropropinoic acid, and preserves growth rate of neurons during exposure to corticosteroids (like cortisol) which can reduce neuron growth rates. Interestingly, the energetic effect also applies to Alzheimer's Disease, where creatine phosphate per se attenuates pathogenesis in vitro, yet creatine per se did not.
These effects are secondary to creatine being a source of phosphate groups and acting as an energy reserve. The longer a cell has energy, the longer it can preserve the integrity of the cell membrane by preserving integrity of Na+/K+-ATPase and Ca2+-ATPase enzymes. Preserving ATP allows creatine to act via a nongenomic response (not requiring the nuclear DNA to transcribe anything), and appears to work secondary to MAPK and PI3K pathways.
A protective effect on neurons by creatine, secondary to its ability to donate phosphate groups, exists and appears to be quite general in its protective effects
When assessing the antioxidant effects of creatine, it does not appear to sequester superoxide and may not be a direct antioxidant. Additionally, creatine failed to protect neurons from H2O2 incubation to induce cell death via pro-oxidative means. These results are in contrast to previously recorded results suggesting creatine as a direct anti-oxidant.
Some reports exist that creatine may be a direct anti-oxidant, but these have failed to be replicated. Creatine most likely does not possess anti-oxidant potential
The concentration of creatine that increases mitochondrial respiration in skeletal muscle (20mM) and this concentration also appears to work similarly in hippocampal cells. This promotes endogenous PSD-95 clusters and subsequently synaptic neurogenesis (thought to simply be secondary to promoting mitochondrial function).
Mitochondrial function per se appears to promote neuronal growth and proliferation, and at least in vitro, creatine is known to do the same and promote growth
One of the studies noting a reduction in fatigue in healthy subjects given creatine (8g) for five days prior to a mathematical test noted a relative decrease in oxygenation hemoglobin in the brain and an increase in deoxygenated, which normally indicates a reduction in cerebral oxygenation. The authors made note of how cytoplasmic phosphocreatine can increase oxygen uptake into cells (noted in vitro in a concentration dependent manner between 0-25mM) and suggested that either cells were taking up more oxygen from hemoglobin, or that increased mitochondrial efficiency resulted in less of a need for oxygen.
Creatine has been sought after for its effects on depression, due to the significant changes occurring in brain morphology and neuronal structure associated with depression and low brain bioenergetic turnover in depression, perhaps related to abnormal mitochondrial functioning, which reduces available energy for the brain. The general association of low or otherwise impaired phosphate energy systems (of which creatine forms the energetic basis of) with depression, has been noted previously. Due to associations with cellular death and impaired bioenergetics with depression, creatine was subsequently investigated.
Oral ingestion of 1-1000mg/kg bodyweight of creatine in mice was able to exert an anti-depressive effect, which was blocked by dopamine receptor antagonists. A low dose of creatine (0.1mg/kg) was able to enhance the dopaminergic effects of dopamine receptor activators, suggesting supplemental creatine can positively influence dopamine signalling and neurotransmission.
Mechanically, creatine may exert anti-depressant effects via mixed dopaminergic and serotonergic mechanisms. The exact mechanisms are not clear at this time
Anti-depressive effects have been noted in humans, where 5g of creatine monohydrate daily for 8 weeks was able to augment the efficay of SSRI anti-depressants. Benefits were seen at week two and were maintained until the end of the 8 week trial. These effects were noted before in a preliminary study of depressed adolescents (with no placebo group) showing a 55% reduction in depressive symptoms at 4g daily when brain phosphocreatine levels increased. Other prelimnary human studies suggest creatine might lessen unipolar depression and one study on Post-Traumatic Stress Disorder (PTSD) noted improved mood as assessed by the Hamilton Depression Rating Scale.
It is possible that females could benefit more than males due to a combined lower creatine kinase activity as well as having altered purine metabolism during depression, but no human comparative studies have been conducted yet. One rat study noted that creatine monohydrate at 2-4% of feed had 4% creatine able to exert anti-depressive and anxiolytic effects in female rats only.
Intervention studies with creatine supplementation and depression show promise, but only one well conducted study (used alongside SSRI pharmaceuticals) has been done, while other studies have flaws. Promising, but no conclusions can be made at this time
Most causes of brain injury (calcium influx, excitotoxicity, lipid peroxidation, reactive oxygen intermediates or ROIs) all tend to ultimately work secondary to damaging the mitochondrial membrane and reducing its potential (which ultimately causes cellular apoptosis). Traumatic brain injuries are thought to work vicariously through ROIs by depleting ATP concentrations. Creatine appears to preserve mitochondrial membrane permeability in response to traumatic brain injury (1% of the rat's diet for four weeks) which is a mechanism commonly attributed to its ATP buffering ability.
Brain injuries tend to cause continued damage to cells, secondary to ATP depletion, and creatine appears to preserve mitochondrial membrane permeability in response to brain injury, which is thought to be due to its ability to preserve ATP
In rats and mice given creatine injections (3g/kg) for up to five days prior to traumatic brain injury, supplementation was able to reduce brain injury by 3-36% (time dependent, with five days being more protective than one or three), and dietary intake of creatine at 1% over four weeks halved subsequent injuries.
Daily intake of creatine in rats appears to be capable of halving the effects of brain injuries
In children and adults with tramautic brain injury (TBI), six months of creatine supplementation of 400mg/kg bodyweight appears to significantly reduce the frequency of headaches (from 93.8% to 11.1%), fatigue (from 82.4% to 11.1%), and dizziness (from 88.9% to 43.8%), relative to unblinded control.
Preliminary evidence suggests that headaches and dizziness associated with brain injury can be attenuated with oral supplementation of creatine
Due to a combination of its neuroprotective effects and dopaminergic modulatory effects, creatine has been hypothesized in at least one review article to be of benefit to drug rehabilitation. This study used parallels between drug abuse (usually methamphetamines) and traumatic brain injury and made note of creatine being able to reduce symptoms of brain trauma such as headaches, fatigue, and dizziness in clinical settings in two pilot studies. No studies currently exist that look at creatine supplementation and drug rehabilitation.
Acute administration of creatine (intra-cranial) appears to enhance learning from a previous stimuli, vicariously through the NDMA receptor and was enhanced via coincubation of spermidine, which amplifies NMDA currents.
In rats, an enhancement of spatial learning appears to be apparent and mediated via the NMDA receptor; a similar mechanism to preliminary studies in D-Aspartic Acid
Studies conducted in vegetarians tend to show cognitive enhancement in youth, possibly due to a creatine deficiency, as compared to omnivores. Vegetarian diets have lower levels of circulating creatine prior to supplementation, but attain similar circulating levels as omnivores when both supplement. Building on this latter point, supplementation of creatine monohydrate in a loading protocol (20g daily in orange juice) in omnivores does not alter levels of creatine in white matter tissue in the brain (test subjects: competitive athletes). On most of the parameters that vegetarians experience benefits, omnivores fail to experience statistically significant benefits, except possibly when sleep deprived, where the cognitive improvements rival that seen in vegetarians. Elderly people who are omnivorous may also experience increases in cognition to a similar level, in regards to long-term memory as well as forward number and spatial recall, although the study in question failed to find any significant benefit on backwards recall or random number generation, the latter of which is a test for executive working memory.
Creatine has been demonstrated to increase cognition (memory, learning, and performance) in people with no dietary creatine intake (vegetarians and vegans). These benefits also appears to extend to the sleep deprived and elderly people without any saliant cognitive decline
In a rested state, young omnivores may experience an increase in reaction speed.
One study that did not control for dietary or lifestyle choices, but was conducted in young healthy adults, noted that 8g of creatine supplementation daily (spread out in multiple doses) for 5 days was able to reduce fatigue during a mathematical test (Uchida-Kraepelin test).
Creatine has limited potential in increasing cognition in otherwise healthy young omnivores, but it does possess a general pro-cognitive effect
5g of creatine four times daily for a week (loading) before sleep deprivation for 12-36 hours was able to preserve cognition during complex tasks of executive function at 36 hours only, without significant influence on immediate recall or mood. A similar protocol replicated the failure to improve memory and attention, but noted less reports of fatigue (24 hours) and less decline of vigor (24 hours) although other mood parameters were not measured.
The creatine kinase (CK) enzyme in rat heart tissue appears to have a KM around 6mM of creatine as substrate and is known to positively influence mitochondrial function as higher cytoplasmic phosphocreatine concentrations (not so much creatine per se) increase the oxidative efficiency of mitochondria. This is thought to be due to the transfer of high energy phosphate groups.
The heart expresses the CK enzyme and system to a larger degree than any other tissue in the mammalian body, and it serves to make mitochondrial activity more efficient
Phosphocreatine is known to be a major source of energy for cardiac tissue alongside fatty acids, which are dominant under periods of normoxia (normal oxygen) while phosphocreatine becomes more important in periods of hypoxic stress. The entire CK system plays a role in the recovery of the heart following ischemic/hypoxic stress, since blocking CK activity impairs recovery and overexpressing CK activity promotes it. This is due to the heart tissue needing high energy phosphate groups at this time, and the ischemic stress reduces CK activity and the ability of CK to donate these groups.
After ischemia, increasing the activity of the creatine transporter (without necessarily influencing CK) to allow more creatine influx has been associated with improving post-ischemic contractility by around 30%.
It seems that the creatine kinase system is important for a heart that underwent a low oxygen stressor (hypoxic stress or ischemia) since the energy it provides is used in the repair process. Higher activity of the creatine kinase system or an influx of creatine into the cell are both seen as beneficial after a cardiac injury
While one study isolating red blood cells (RBCs) from plasma failed to find any creatine kinase or phosphocreatine in the cells extracted from the plasma of volunteers this may be due to the equipment used, as later studies have noted the presence of creatine in RBCs and creatine kinase in the membrane.
The concentration in healthy controls (57+/-8 years) without supplementation of creatine appears to be around 1.24+/-0.26µM per gram of hemoglobin and appears to decrease in concentration during the aging process of the erythrocyte. Otherwise healthy subjects who take a loading phase of creatine (5g four times daily for five days) can experience a 129.6% increase in erythrocytic creatine concentrations from an average value of 418µM (per liter) up to 961µM with a large range (increases in the range of 144.4-1004.8µM), and it appears to correlate somewhat with muscular creatine stores.
Erythrocytic creatine is normally enhanced in instances of splenomegaly or pulmonary arterial hypertension, but it is unaffected in hyperthyroidism, a condition known to be associated with low mean corpuscular volume.
Creatine is expressed in moderate to low levels in red blood cells, and decreases when the erythrocyte normally ages. Supplementation of creatine is able to significantly increase levels of creatine in the erythrocyte to around 1.5mM at maximum, though usually to around 800-1,000µM
Supplementation of a loading phase of creatine has been noted to augment the increase in RBC levels of superoxide dismutase (SOD) from exercise, when measured immediately after, by 8.1%, but control groups increased to match within an hour. Glutathione (normally decreases with exercise) and catalase (increases) were both unaffected, and elsewhere in vitro red blood cells incubated with 3mM of creatine (within the supplemental range) is able to improve filterability (a measure of cell rheology, or fluid structure of the cell) when RBC creatine was increased by 12.3% to reach 554µM. This was thought to be due to reduced oxidative stress (assessed via MDA) in the red blood cells, which in the presence of 1-5mM creatine was progressively reduced by 20-41%.
Very limited evidence suggests that the increase in RBC creatine concentrations is associated with antioxidant effects, which are thought to be protective, and while this likely occurs in humans following supplementation of creatine, the practical relevance of this information is not yet known
Homocysteine is an endogenous metabolite involved in methylation processes in the body, and mildly elevated homocysteine appears to be an independent risk factor for both cardiovascular and atherosclerotic disease, where if the 8-10μM normal range is elevated by around 5μM, it is thought to confer 60-80% greater risk (atherosclerotic disease). Although it may not independently cause problems, it may have a causative role in the context of the whole body system since it is atherogenic by augmenting LDL oxidation and promoting conversion of macrophages into foam cells.
Homocysteine is produced after S-Adenosyl Methionine is used up (as donating a methyl group creates S-adenosylhomocysteine, which then produces homocysteine) mostly from Phosphatidylcholine synthesis and its reduction (via either methylation from Trimethylglycine via betaine:homocysteine methyltransferase, urinary excretion, or convertion into L-cysteine via cystathionine beta-synthase) is thought to be therapeutic for cardiovascular diseases.
Homocysteine is a byproduct of methylation in the body, and when it builds up in the blood it indicates that the subject is at higher risk for cardiovascular diseases like atherosclerotic disease. Its reduction is thought to be therapeutic and reduces the risk of cardiovascular diseases (although this has not panned out in any trial to date)
The synthesis of creatine (from guanidinoacetate via GAMT) also requires SAMe as a cofactor and is implicated in homocysteine production. While supplementation of guanidinoacetate at 0.36% (prior to SAMe) can increase homocysteine by up to 50% in rats, supplementation of creatine (0.4%) is able to suppress homocysteine by up to 25%, secondary to reducing creatine synthesis, and has been replicated elsewhere with 2% of the rat diet, where a loading phase did not alter the benefits.
One case study on a subject with a methylentetrahydrofolate reductase (MTHFR) 677TT homozygote, a relatively common genetic mutation known as 'mild MTHFR deficiency', which causes mild homocysteinemia, has seen benefits due to creatine supplementation where homocysteine was approximately halved (49% reduction) while CT heterozygotes and CC homozygotes (n=9) were unaffected. Additionally, one rat study suggested a possible role for creatine in reducing homocysteine levels in a model of high uric acid levels (model for end stage renal disease) but this failed when investigated in humans.
Reducing creatine synthesis by supplementing it has preliminary evidence in reducing homocysteine concentrations in the body, since the synthesis of creatine would normally produce some homocysteine as a byproduct. This may apply to a certain subset of persons (MTHFR TT homozygotes; about 10% of North Americans) but at the moment there is not enough evidence to suggest that this occurs in all people supplementing creatine
The creatine kinase system appears to be detectable in endothelial cells, and under basal conditions creatine itself is expressed at around 2.85+/-0.62μM (three-fold higher than HUVEC cells). When incubating the medium with 0.5mM creatine, endothelial cells can take up creatine via the creatine transporter (SLC6A8) and increase both creatine (almost doubling) and phosphocreatine (nearly 2.5-fold) concentrations.
When endothelial cells have a higher creatine concentration, they appear to be mildly less permeable when incubated with 0.5-5mM creatine while the higher concentration (5mM) is able to fully ablate TNF-α induced neutrophil adhesion and both E-selectin and ICAM-1 expression. This was prevented with ZM241385, an A2A (adenosine) receptor antagonist, and since adenosine released by this receptor is known to be protective of endothelial cells it is thought that creatine works vicariously through this receptor and adenosine release, thought to be due to releasing ATP (occurs in response to stress) which protects the cell via the A2A signalling system.
Creatine appears to be able to suppress immune cell adhesion to endothelial cells, which is thought to be secondary to increasing phosphocreatine content of the endothelial cells. Oddly, this anti-atherosclerotic effect is inhibited by adenosine antagonists
Human platelets isolated from serum appear to contain creatine kinase and phosphocreatine.
Supplementation of creatine at 20g daily for a loading phase, followed by 10g daily for the rest of the two month trial has resulted in a reduction of total cholesterol (5-6%) and vLDL cholesterol (22%) relative to placebo with no significant influence on LDL-C or HDL-C.
Creatine has been hypothesized to increase serum triglycerides, since it is able to reduce liver fat in a manner similar to Trimethylglycine (TMG), and TMG raises triglyceride levels slightly by releasing them from the liver. Creatine may work in a similar manner.
Since creatine and TMG both reduce liver fat in a similar manner, and TMG is known to increase triglycerides slightly, creatine may also increase triglycerides by the same mechanisms
Supplementation of creatine at 20g daily for a loading phase, followed by 10g daily for eight weeks in healthy volunteers resulted in a reduction of triglycerides by 23%, which remained lower than baseline for four weeks after supplementation was halted, while vLDL (the lipid particle which carries most of the triglyerides which TMG causes to be released from the liver) was also reduced by 22% in this study.
Other human studies have yielded mixed results concerning creatine's influence on triglyceride levels. In healthy male football players, creatine supplementation (5g monohydrate daily) over eight weeks did not influence triglyceride levels but in martial artists given approximately 3.5g daily, a statistically significant increase in triglycerides was found despite no changes in total cholesterol. In people with cardiovascular complications, given an exercise program and creatine, no significant change in triglycerides was noted relative to a placebo control group, also performing exercise.
Unlike TMG supplementation, there appear to be unreliable influences of creatine supplementation on serum triglycerides. Two null studies show no influence, while two others show an increase and a decrease, respectively. The reason for this variance is not yet known
GLUTs are vesicle transporters that are the rate-limiting steps for bringing glucose into a cell, and GLUT4 is the most active variant. Agents that reduce blood glucose (insulin or AMPK) are known to act via mobilizing GLUT4, and increased GLUT4 expression and activity is indicative of a greater ability to bring glucose into a cell while reducing it impairs glucose uptake. Rat studies have confirmed that creatine feeding increases muscular GLUT4 expression associated with increased insulin-stimulated glucose uptake.
Supplementation of creatine at 5g daily alongside rehabilitation (after limb immobilization for two weeks while taking 20g daily) is associated with a preservation in GLUT4 levels, which were reduced during immobilization. During exercise rehabilitation, it increased to 40% above placebo. This study failed to note an increase in GLUT4 in control (despite exercise normally doing so) thought to be due to the low frequency of activity. Thus creatine was thought to augment the increase (insignificant due to low exercise) to significant levels. Elsewhere, creatine has increased GLUT by approximately 30% relative to control, but it failed to reach statistical significance. This study did not issue an exercise protocol.
The attenuation in GLUT4 and the subsequent increase seemed to occur alongside attenuations and increases in phosphocreatine, but not glycogen, which declines in the last measurement.
Creatine supplementation appears to attenuate decreases in GLUT4 expression seen with immobility and may increase GLUT4 expression during exercise. While it seems capable of increasing GLUT4 during resting conditions, it has failed to reach significance, suggesting that creatine supplementation works best with some stimuli associated with exercise
It is known that intracellular energy depletion (assessed by a depletion of ATP) stimulates AMPK activity in order to normalize the AMP:ATP ratio, and when activated AMPK (active in states of low cellular energy and colocalizes with creatine kinase in muscle tissue) appears to inhibit creatine kinase via phosphorylation (preserving phosphocreatine stores but attenuating the rate that creatine buffers ATP). While phosphocreatine technically inhibits AMPK, this does not occur in the presence of creatine at a 2:1 ratio. It seems that if the ratio of phosphocreatine:creatine increases (indicative of excess cellular energy status) that AMPK activity is then attenuated, since when a cell is in a high energy status, there is less AMP to directly activate AMPK.
Inducing a creatine deficiency, despite its negatives, is able to activate AMPK at higher than normal levels, similar to how abolishing mTOR (a regulator of muscle protein synthesis that is also antagonistic to AMPK) causes a relative increase of AMPK activity.
Cellular systems active in high energy conditions (mTOR, creatine kinase) are negative regulators of those cellular systems active in low energy conditions (AMPK). Due to this, a high cellular phosphocreatine concentration (specifically, the ratio of phosphocreatine to creatine) appears to suppress AMPK activity
Increasing creatine levels in a skeletal muscle to 687% of baseline (0.5mM creatine, thought to be equivalent to 5g creatine) doesn't seem to per se increase glucose uptake, but increases glucose oxidation (140% of baseline) which is due to a 2-fold increase in the activity of α1 and α2 subunits of AMPK, a potency comparable to 1mM of the reference drug AICAR. Glucose uptake associated with AMPK has indeed been noted in diabetics who are undergoing physical exercise and in skeletal muscle cells being contracted but according to rat and in vitro studies of cells not being contracted this is not a per se effect of non-exercising tissue but only an augmentation of an exercise-induced glucose uptake.
Despite the above antagonism that occurs with high energy states (creatine kinase) and low energy states (AMPK), it seems that supplementation of creatine actually increases the ability of AMPK to act under conditions of physical exercise and muscle contraction
Creatine is known to increase skeletal muscle cellular volume alongside increases in water weight gain. Since glycogen itself also increases the osmolytic balance of a cell (draws in water) and preliminary evidence shows a strong trend of creatine augmenting glycogen loading, creatine is thought to be related to an increase in cell volume, which is known to promote glycogen synthesis.
Both creatine and glycogen seem to be positively correlated with one another in muscle cells, and when one increases the other tends to increase as well. Due to this, creatine supplementation is thought to have a role in glycogen loading and replenishment
Creatine has been found to increase skeletal muscle glycogen when given to sedentary adults for a loading and maintenance phase for 37 days at 2g (13.5% after five days of loading, but returning to baseline at the end of the trial). Exercise was not enforced in this study. This study also noted that despite a normalization of glycogen after the trial, total creatine and ATP was still higher than placebo, and a loading protocol appears to have failed elsewhere in increasing glycogen stores in sedentary persons subject to an aerobic exercise test before and after the loading phase.
In participants subject to glycogen depletion via exercise, it was noted that the 41% increase in glycogen in the control group (exericse and glycogen repletion diet) was increased to 53% under the context of creatine loading.
When looking at how glycogen is influenced under supplementation of creatine, creatine supplementation appears to enhance the accumulation and synthesis of glycogen in skeletal muscle when coingested with carbohydrates
In instances where creatine augments glycogen accumulation into muscle, the coingestion with carbohydrate has failed to further increase creatine loading into the muscle relative to control. Supplementation of creatine after exercise increased intramuscular creatine levels by 37% in the nonexercised leg and 46% in the exercised leg.
When looking at creatine stores under the influence of glycogen, increasing glycogen replenishment rates with creatine supplementation does not appear to increase the amount of creatine that actually enters the cell
In otherwise sedentary and healthy men, given a loading phase of creatine followed by 11 weeks of maintenance, the glucose response to an oral glucose tolerance test is reduced by 11-22% (measurements at 4-12 weeks with no time dependence noted) which was not associated with changes in insulin levels or sensitivity. Elsewhere, a study in vegetarians (5g daily for 42 days) failed to find a reduction in postprandial blood glucose.
The glucose response to a meal is either attenuated or not affected by creatine supplementation
Studies on humans, investigating the insulin response to a meal, have failed to find a significant influence of creatine supplementation (3-5g) including in otherwise healthy vegetarians given 5g creatine for 42 days (no influence on fasting nor postprandial insulin levels).
Creatine appears to be able to stimulate insulin secretion in vitro (isolated pancreatic cells), but this does not appear to apply to oral creatine supplementation since both fasting insulin and the insulin response to a meal are unchanged
One study on 27 otherwise healthy men supplementing creatine (0.3g/kg loading for a week, 0.05g/kg thereafter for 8 weeks) with a thrice weekly exercise regiment noted that alongside greater increase in lean mass and power relative to placebo at 4 and 8 weeks, that myostatin in serum decreased to a greater extent with creatine (around 17% at 8 weeks; derived from graph) than it did with placebo (approximately 7%). Increases in GASP-1, a serum protein that inhibits the actions of myostatin by directly binding to it, was not different between groups.
A suppression of myostatin has been noted with supplementation of creatine, which is not associated with GASP-1 (which normally suppresses myostatin). This theoretically leads to an increase in muscle growth since myostatin would suppress it
Supplementation of creatine during rehabilitative exercise in otherwise healthy adults has been noted to suppress an increase in myogenin protein content, yet increase MRF4 protein content, with no apparent influence on Myf5 nor MyoD.
Some alterations in local myogenic signalling factors have been noted, but the exact role and significance of these is not yet known
In regards to carbohydrate oxidation during exercise, it appears that rats subject to intermittent physical exercise (utilizes glycogen) have decreased lactate production during said exercise, suggesting a preservation of glycogen usage. This occurred alongside an increase in glycogen stores. This is thought to be due to phosphocreatine donating phosphate to replenish ATP and without any changes in whole body metabolic rate it indirectly causes less glucose to be required to replenish ATP, due to a quota needing to be met during exercise, and creatine phosphate taking up a relatively larger percentage of said quota.
In humans, supplementation of 2g creatine for six weeks after a five day loading period has failed to alter performance in aerobic cycling tests and does not alter the rate of whole body oxidation (a measure of metabolic rate during exercise).
Creatine is used up as energy during high intensity exercise. Due to this usage, the amount of glucose required (from glycogen) is decreased a bit; this both preserves glycogen concentrations in skeletal muscle and reduces lactate production, which is produced when glucose is oxidized for energy. There do not appear to be any alterations in the bioenergetic status of muscle cells during low to moderate intensity exercise
Homocyteine (normal serum range of 5-14µM) is known to adversely affect motor control in genetically susceptible people, when their levels exceed 500µM, usually associated with genetically induced deficiencies of B12. In this particular instances (assessed by rats fed homocysteine to increase serum levels to such a high level) it appears that administration of 50mg/kg creatine (injections) to these rats can protect dysfunction in muscle metabolism (pyruvate kinase activity, Krebs cycle intermediates, and muscle cell viability) induced by homocysteine.
Homocysteine is produced during exercise, due to creatine synthesis, in otherwise healthy people and in older sedentary men, although only very mildly and not to clinically relevant levels), and creatine can reduce this mild increase during both anaerobic and aerobic exercise in rats.
Creatine may protect muscle cells in instances of very elevated homocysteine (B12 deficiencies and genetic defects) based on preliminary animal evidence. Although it can also prevent a homocysteine increase from exercise, the increase in homocysteine from exercise appears to be very small and this likely isn't a practical concern
When assessing type I muscle (slow twitch) against type II muscles (fast twitch) in response to creatine supplementation, it seems that glycogen accumulation may only occur in the latter as assessed in rats, where the soleus muscle is a model for slow twitch muscle fibers and the gastrocnemius is a model for fast twitch. This is similar to human creatine distribution, which seems to accumulate in type II muscles rather than type I.
Using information from a meta-analyses of 16 studies conducted on creatine and its influence on power and strength, (with or without exercise in all age groups above 16, but placebo controlled and without crossover) studies that tended to have a 5-7 day loading period with continued maintenance thereafter noted that, in regards to studies assessing 1-3 rep bench press strength in trained young men, that 7 studies (four of which are online) totalling 70 people using creatine and 73 persons in placebo resulted in a 6.85kg increase in strength relative to placebo, the benefits of which peaked at 8 weeks. This meta-analysis also quantified a significant increase in squat strength (9.76kg) yet failed to find a significant influence on peak biceps contraction power, which may have been influenced by the two null studies being in elderly persons while the positive study was statistically outweighed, but noted an 1.8-fold increase in power associated with creatine over placebo. The other meta-analysis conducted the following year calculated effect sizes for creatine supplementation and noted no significant differences between genders or when comparing trained against untrained individuals. The mean effect size of exercises lasting below 30s (those that use the creatine-phosphate system) was 0.24+/-0.02 and performed significantly better than placebo, where exercise increased performance by 4.2+/-0.6% while the addition of creatine enhanced this to 7.5+/-0.7%.
According to the two meta-analyses on the topic, Creatine significantly increases power when supplemented in both sexes over a period of time up to 8 weeks (where improvement over placebo is maintained, rather than being enhanced further). The rate of which power is derived from a resistance training regimen appears to be up to 78.5% greater with creatine relative to placebo, and in active trained men who are naive to creatine, this can be quantified at about 7kg for bench and 10kg for squat over 8 weeks
Resistance exercise enhances the rate of creatine uptake into muscle cells in the muscles that are actively engaged. Initially thought to be a byproduct of enhanced blood flow, the enhanced creatine uptake is now thought to be due to allosteric modifications of the creatine transporter, which enhances its maximal capacity.
One study reported elevated creatine uptake in response to supplementation (and independent of exercise) in athletes versus non-athletes, suggesting that long-term modifications in muscle tissue is a by-product of exercise.
Creatine supplementation can also increase muscle fiber size independent of protein synthesis, as increasing water content in muscle cells increases their diameter. After 20g creatine was ingested (alongside dextrose at a 1:7.5 ratio) type I, IIa and IIx fibers increased in diameter by 9, 5, and 4% respectively.
This cellular influx may also decrease protein oxidation rates, which leads to increases in nitrogen balance and indirectly increases muscle mass. This lowering of protein oxidation is from signalling changes vicariously through cell swelling and appears to upregulate 216 genes in a range of 1.3 to 5-fold increases, with the largest increase seen in the protein involved in satellite cell recruitment, sphingosine kinase-1. Most importantly for muscle hypertrophy, the protein content of PKBa/Akt1, p38 MAPK, and ERK6 increased 2.8+/-1.2 fold. Sixty-nine genes are also downregulated after creatine supplementation, to less notable degrees.
12g of creatine for two weeks prior to an endurance running test (65-70% VO2 max for an hour) is able to attenuate the increase in lactate and the tryptophan/Branched Chain Amino Acids ratio, and also attenuated the increase in serum protein catabolites, suggesting an anti-catabolic effect.
One study in swimmers using 2g of creatine daily failed to find an increase in skeletal muscle creatine content and did not find any alterations in skeletal muscle metabolism during exercise relative to placebo.
The lowest dose of creatine sufficient to increase muscular creatine stores in otherwise healthy but sedentary persons (2 grams) appears to be insufficient for athletes
In otherwise healthy bodybuilders, supplementation of creatine at 5g either immediately before or after a weight training session (with no directive on days without training) over the course of four weeks noted that while both groups improved, there was no significant difference between groups overall. It was suggested that post-workout was better, based on magnitude-based inference, since on a per case basis more individuals experienced benefits in post-workout ingestion rather than preworkout ingestion.
While one study has suggested a possible benefit with post-workout ingestion relative to pre-workout, the magnitude of benefit was not enough to reach statistical significance
Higher percieved effort during heat (or due to elevations in body heat) are thought to be mediated by either the serotonergic system (suppresses performance) or the dopaminergic system (enhanced performance), and creatine is thought to be involved in percieved effort during heat training since it has been noted previously to interact with neurotransmission by enhancing both serotonergic and dopaminergic neurotransmission.
When exercising in heat, supplemental creatine (loading phase with carbohydrates) appears to be able to reduce symptoms of hyperthermia, such as perceived physical exertion, and despite physical performance enhancement only occurring in responders, the benefits of heat tolerance occurred in both groups of people.
Endurance exercise is also known to produce heat from skeletal muscle tissue, and an increase in internal temperature occurs when the production of heat (from metabolism) exceeds release. This increase in heat is accelerated when training in hot environments and it is thought to be beneficial to retain water (hydration) during exercise, since more water allows a preservation of plasma volume (PV) and the sweat response reduces internal temperature. This particular phenomena may only apply to endurance exercise, since creatine is able to increase sprint performance in heat, independent of altering the decline in PV and sweat rates.
Creatine supplementation (11.4g) with glycerol (1g/kg; per se effective) and glucose (75g) in endurance runners in the heat appears to attenuate the increase in internal temperature associated with an increase in total body water of 0.71+/-0.42L, while performance (VO2 max and running economy) were unaffected over 30 minutes. Creatine is effective without glycerol (20g daily with 140g of glucose polymer over a week) again without an improvement in physical performance.
In nonelite swimmers conducting an intermittent sprint protocol (Six 50m sprints every two minutes), supplementation of a creatine loading period was able to reduce the decrement in speed during the third sprint (2% decrement rather than a 5% decrement) but not the sixth sprint. There were no changes in plasma lactate or other biomarkers of fatigue. When examining a single 50m sprint in amateur swimmers, a loading period of creatine is able to reduce the time to complete the sprint by 4.6%, while it had no benefit for the 100m sprint and when the loading phase was followed by three weeks maintenance in youth, there is no apparent benefit to sprint performance (50m sprint with five minutes rest followed by a 100m freestyle) despite benefits to a swim bench test (30s sprints with a five minute break in between).
One study in elite swimmers subject to sprints (varying in length from 25-100m) failed to find benefit with creatine supplementation, although there was also a failure on leg extension strength, suggesting nonresponse. This has been noted elsewhere with a similar protocol twice, while one study in elite swimmers subject to single 50m or 100m sprints found benefit with supplementation and one found benefit with six repeated 50m sprints by 2%, yet not ten repeated 25m sprints with elite male swimmers (females failed to find benefit) and another also noted benefit in elite swimmers on a sprinting protocol. Overall the evidence is quite limited and suggests either a mild, or more likely, no increase in elite swimmers, although one study confirming an increase in body and water weight failed to find a decrement in performance.
The majority of studies have used nothing but a loading period and the study, overall, lasted for a week or so. This is partially because one study that noted benefit with a loading period failed to note benefit with prolonged supplementation and that lowballing supplementation at 2g a day in high active swimmers does not appear to be sufficient to alter any function in skeletal muscle.
If there are any benefits with creatine supplementation and swimming performance, they appear to be limited to a 50 meter sprint or a handful of 50 meter sprints with short intermissions. Excessive sprinting (over six sprints with short breaks) or too long of a break (five minutes rather than two) seem to not be associated with the benefits of creatine supplementation
In elite swimmers, 20g of creatine for five days followed by 3g (with 7g glucose) for 22-27 weeks before another loading session failed to improve performance during training sessions (measured by training volume) during the maintenance phase and failed to improve either sprint or endurance performance relative to placebo.
A study using a loading and maintenance phase in elite swimmers during their competitions (rather than a controlled experimental environment) has failed to find benefit with supplementation of creatine
As mentioned earlier, supplementation of creatine in youth has been noted to improve the swim bench test (a thirty second sprint followed by another after a five minute break). One study has noted improvement when looking at a 400 meter test when 10g of creatine was taken over seven days with some orange juice. The improvement was mostly attributable to increased performance on the last 50m stretch.
Contrary to the popular belief that creatine only enhances short term performance, in swimmers it appears that more prolonged swimming trials see benefit with creatine supplementation by preserving performance in the final stretches
The recovery period in between sprint sets is known to be associated with a phosphocreatine regeneration rate and this resynthesis rate is highly associated with actual physical performance during the sprints.
Creatine supplementation at 300mg/kg for one week (loading with no maintenance) in youth subject to six repeated 35m sprints (10s rest; known as the Running-based Anaerobic Sprint Test or RAST) noted that the increased average and peak power output seen in creatine was not met with a reduction in fatigue, although there was an attenuation in inflammation from exercise (TNFα and CRP).
When examining repeated sprinting tests (sprint, rest a minute or less, repeat) the rate of phosphocreatine resynthesis appears to be a positive influence on performance and supplemental creatine appears to be beneficial
Creatine supplementation appears to be effective at increasing power output in anaerobic cardiovascular exercise, and has been implicated in increasing the lactate threshold as well as time to volitional fatigue within 6 days after stating supplementation (20g daily, divided into 4 doses with 15g glucose).
Some studies note no significant benefit, although at least one author has suggested this may be due to calculation errors. Regardless, there is still some counter evidence that is not subject to said calculation errors that suggest no statistically significant benefit.
Supplementation of 20g creatine (as dicreatine citrate) daily for five days failed to influence VO2 max or any other parameter of endurance in a study where body mass was unaffected.
In well trained endurance runners, creatine (with glycerol for hyperhydration) caused a relatively large increase in body weight gain (0.90+/-0.40kg) and water weight (0.71+/-0.42L) but failed to negatively influence performance over 30 minutes in the heat, and this failure to improve physical performance in the heat with creatine loading (despite water retention) has been noted elsewhere.
When examining studies with prolonged cardiovascular exercise (ie. jogs and marathons, but not sprints) creatine supplementation has failed to show significant improvement, although it seems that the potential ergogenic benefits (too small to be statistically significant) may prevent the weight gain from creatine from suppressing performance
Osteoblast cells are known to express creatine kinase. Bone growth factors such as IGF-1, PTH, and even Vitamin D seem to induce bone growth alongside increases in creatine kinase activity. Vitamin D has been noted to work indirectly by increasing the cellular energy state (these hormones increase creatine kinase in order to do so), in order to make bone cells more responsive to estrogen. This evidence, paired with enhanced growth rates of osteoblasts in the presence of higher than normal (10-20mM) concentrations of creatine suggest a role in creatine in promoting osteoblastic and bone growth, secondary to increasing energy availability.
A higher energy state in osteoblasts (via either higher creatine kinase activity or increase ATP availability) appears to be positively associated with greater growth and differentiation, and creatine incubation in osteoblasts appears to be sufficient to enhance the cellular energy state
In otherwise healthy adults subject to leg immobilization for two weeks while taking 20g creatine daily during immobilization and then 5g daily during eight weeks of rehabilitation, it was noted that the creatine group failed to reduce atrophy during the immobilization (10% reduction in cross sectional area and 22-25% reduction in force output) despite preventing a decrease in phosphocreatine, yet significantly enhanced the rate of regrowth and power recovery. A similarly structured and dosed study has also noted greater expression of skeletal muscle, GLUT4 expression and a 12% increase in muscle phosphocreatine content.
The results mentioned above differ from other study results, where creatine at the loading dose (20g) for a week prior to one week of arm immobilization was able to attenuate lean mass. This study never specified muscle cross sectional area or water weight, however.
Creatine supplementation does not appear to reduce the rate of muscle loss during immobilization, but appears to enhance muscular rehabilitation afterwards
In older individuals subject to knee arthroplasty, 10g of creatine for the ten days leading up to surgery and 5g each day afterward did not modify weight loss from the surgery nor was recouperation (assessed by walking distance) enhanced with creatine supplementation.
When measuring the blood following a sprint test performed two weeks after starting 12g of creatine daily in athletes, there was an increase in urinary hydroxyproline concentrations, which the authors suggested may be related to an increase in collagen breakdown.
One study investigating the effects of creatine supplementation on people with osteoarthritis given knee arthroplasty (surgical procedure for osteoarthritis), who received creatine at 10g daily for 10 days prior to surgery and 5g daily for a month afterwards failed to find benefit with supplementation. This study failed to find any differences in muscular creatine stores or weight changes.
In older women with knee osteoarthritis, given supplemental creatine at 20g for five days followed by 5g for the rest of the twelve week trial, supplementation was associated with improvements in stiffness (52% reduction), pain (45%), and physical function (41%) as assessed by WOMAC, despite no improvements in physical power output relative to placebo. This study paired supplementation and placebo with a mild exercise regimen.
In young rats given creatine in the diet at 2% of the diet for eight weeks, supplementation appears to increase bone mineral density (BMD) in the lumbar spine with a nonsignificant trend to increase BMD in the femur. Despite the trend, the femur appeared to be 12.3% more resistant to snapping from mechanical stress associated with increased thickness. Menopausal rats (ovarectomized) see similar benefits, as supplementation of creatine (300mg/kg) for eight weeks during ovarectomy is able to increase phosphorus content of the bone and other biomarkers of bone health (although bone stress resistance was not tested).
In spontaneously hypertensive rats (reduced bone mass since they peak earlier and, overall, accrue less bone mass before degradation occurs), creatine supplementation at 0.5% of the young rat's diet over nine weeks failed to significantly influence bone mineral content or density.
Animal evidence at this moment shows promise for creatine's effects on bone mass, but a study in spontaneously hypertensive rats failed to find any benefits for unknown reasons
Creatine has been shown to influence androgen levels. Three weeks of creatine supplementation has been shown to increase dihydrotestosterone (DHT) levels, as well as the DHT:testosterone ratio with no effects on testosterone levels. Furthermore, creatine supplementation, when paired with Beta-Alanine has been shown to increase testosterone levels. Both of these effects were chronic in nature, as low dose creatine supplementation does not acutely increase androgen levels.. However, acute dosing of creatine at higher levels (100mg/kg) has been shown to elicit a moderate increase in testosterone levels.
One study in male amateur swimmers noted that the loading phase (20g daily for six days) was able to increase testosterone levels by around 15% relative to baseline.
Creatine appears to increase DHT and androgen-like effects in the body of men. No studies on women currently exist
A pilot study in otherwise healthy men at rest, given a single bolus of 20g creatine noted a spike in growth hormone secretion over the next six hours with a high variability of 83+/-45%.
In elite swimmers, the growth hormone response to sprints appears to be attenuated (39%) following creatine loading, although after a 3g maintenance phase (22-27 weeks), this attenuation was reduced to less than 5%. Elsewhere in swimmers, resting growth hormone is unaffected by the loading phase, suggesting that this is an exercise exclusive effect.
Creatine may increase growth hormone secretion at rest while being able to blunt exericse-induced growth hormone secretion somewhat. The blunting effect is small in magnitude in maintenance and larger during loading. This is similar to the interactions with Arginine and growth hormone
The cortisol fluctuations during sleep deprivation are not significantly influenced by creatine supplementation and a similar protocol elsewhere noted that while the cortisol changes during sleep deprivation were unaltered, the creatine group appeared to be at a lower basal cortisol level (first measurement taken after loading).
In swimmers given a loading phase of creatine, there was no significant influence on basal creatine concentrations and this lack of effect has been replicated elsewhere with 20g of creatine over a week in otherwise healthy people.
The aldosterone increase in response to exercise (224%) appears to be slightly but significantly enhanced in response to creatine supplementation (263%) when the subjects are exercising in the heat. Resting aldosterone was unaffected by a week of creatine loading. Both ANP and the angiotension enzymes are unaffected.
Serum catecholamines during sleep deprivation and prior to sleep deprivation (after creatine loading) are unaltered with creatine supplementation, relative to placebo.
Macrophages are known to express creatine kinase and to take creatine up from a medium initially by a sodium dependent mechanism (likely the creatine transporter) in a saturable manner, with a second component that requires there to be no concentration gradient to work against (likely passive diffusion) but tends to only account for up to 10% of total uptake in the physiological range (20-60µM). Supraphysiological range was not tested.
The process of phagocytosis (a macrophage consuming a pathogen) in macrophages appears to be associated with an acute reduction in creatine phosphate stores (45%) and an increase in creatine kinase activity, although prolonged stimulation is met with an increase in creatine phosphate (20%). The creatine kinase activity does not appear to be altered based on creatine availability, but since ATP seems to be preserved at these times, the increase in phosphocreatine may be explained by an overall creatine pool paralleling that found in medium.
The process of phagocytosis in macrophages appears to require ATP, and since ATP is stable during the process of phagocytosis, yet phosphocreatine is depleted, it appears that creatine is the major fuel source for macrophages
Creatine and creatinine (100µM in RAW264.7 macrophages) both seem to downregulate the TLR2 receptors, mRNA, and protein levels to less than half of control, with TLR4 and TLR7, but not TLR3, having similar suppression by creatine but less by creatinine. Creatine has been noted to be anti-inflammatory previously.
Creatine and creatinine may have some anti-inflammatory and/or immunosuppressive activities on macrophages, associated with suppressing the receptors that respond to inflammation. Practical significance of this information is not known at this time
Neutrophils are known to produce ATP from lactate derived from extracellular glucose. There is a small glycogen content within the neutrophil to be drawn upon in periods of no glucose availability. There appears to be a phosphocreatine content, but it may be too small to be relevant.
Neutrophils express the creatine kinase system, but at very low levels, which may not be practically relevant
A study isolating T cells from plasma failed to find any expression of creatine kinase nor detection of phosphocreatine.
A study isolating B cells from plasma failed to find any expression of creatine kinase nor detection of phosphocreatine.
In a mouse model of allergin-induced asthma where mice, sensitized by ovalbumin for three weeks and then given 500mg/kg creatine, supplementation induced an increase in asthmatic hyperresponsiveness to low but not high doses of methacholine. This hyperresponsiveness was associated with increased eosinophil and neutrophil infiltration into the lungs, and an increase in Th2 cell cytokines (IL-4 and IL-5) alongside an increase in IGF-1, which is known to influence this process. Interestingly, there was a nonsignificant increase in responsiveness in mice not sensitized to ovalbumin.
It was later noted that creatine was able to nonsignificnatly augment various proinflammatory cytokines (CCL2, iNOS, ICAM-1, TGF-β, TIMP-1) and the presence of eosinophils in lung tissue, as well as to per se cause lung infiltration of these immune cells without requiring the presence of the allergen. Neutrophils and macrophages were unaffected, reflecting the past study of no influence on macrophages, but the only instance where creatine appeared to either significantly add to ovalbumin or to per se induce statistically significant increases were in IL-5 secretion and goblet cell infiltration, although VCAM-1 expression was close. While creatine per se increased nF-κB activity, it suppressed the ovalbumin induced increase.
Preliminary animal research suggests a possible minor proallergic role which needs further research
It was later noted that low to moderate intensity aerobic exercise itself was able to induce protective effects against the aforementioned allergic changes and is able to prevent creatine supplementation (500mg/kg) from exerting these deliterious effects on lung tissue in mice.
Aerobic exercise will inherently cause anti-allergic effects in the lungs, and it appears that it can override the allergen sensitizing effects of creatine supplementation
Creatine has been incubated in various cell lines (HUVEC, C2C12, U937) and noted to reduce cellular death from various pro-oxidant stressors such as H2O2 or peroxynitrate in an intracellular range between 0.1-10mM. This protective effect was only noted with preincubation and was comparable to 10-100µM of Trolox. This protective effect did not require conversion into phosphocreatine nor a buffering of ATP, and only worked during a preloading to the stressor rather than in a rehabilitative manner.
This protection in muscle cells has been noted to preserve cell structure and the concentrations of muscle building factors (MyoD, MRF2, IGF-1). This was not observed with general antioxidants such as Trolox or N-Acetylcysteine despite all three preserving ATP.
Creatine preincubation in a cell appears to confer protection against oxidant stresses, and a direct antioxidant mechanism (like Vitamin C) is doubtful since it needs to be preloaded prior to the stressor and does not work in a rehabilitative manner
Although it does not appear to influence baseline antioxidant enzymes (measured in red blood cells), one week of creatine loading in otherwise healthy young adults has increased red blood cell (RBC) content of the superoxide dismutase (SOD) enzyme in response to a sprint test by 8.1% immediately after exercise. This was no longer detectable after an hour since placebo increased to match. Glutathione and catalase are unaffected.
The increase in serum lipid peroxidation (MDA) seen with exercise is not affected by a creatine loading phase in young athletes.
Despite not interfering with UV(A) irradiation acting upon a cell or the production of oxidation due to it, creatine appears to prevent the functional consequences (such as mitochondrial DNA damage) due to preventing an ATP depletion in the cell, which would normally precede a reduction in mitochondrial membrane potential and mutagenesis but is prevented for as long as creatine stores are sufficient. Creatine has also been noted to near-fully protect mitochondrial DNA from hydroxyl radicals and oxidative damage, although there was no protective effect against nuclear DNA, due to it being less sensitive to hydroxyl radicals.
The energy buffering ability of creatine appears to able to protect cells from excessive DNA damage induced by free radicals, which seem to, in part, work through ATP depletion. This appears to be more protective of mitochondrial DNA than it is of nuclear DNA
The increase in DNA damage caused by a single bout of physical exercise, assessed by urinary 8-OHdG, appears to be partially attenuated by a creatine loading phase for seven days in otherwise healty people, with testing immediately after and compared to placebo.
Limited evidence suggests a reduction, but not abolishment, in DNA damage caused by physical exercise with creatine supplementation
In rats experiencing toxic levels of doxorubicin (a chemotherapeutic agent), creatine supplementation at 0.2g/kg for 30 days appeared to significantly protect rats from death and reduced serum levels of LDH and ALT. The two enzymes were further reduced with the addition of 0.25mg/kg Vitamin C and 400IU/kg Vitamin E.
In rats, creatine supplementation appears to attenuate the damage induced by cytotoxic agents
In children with lymphoblastic leukemia, who are maintaining corticosteroid chemotherapy, creatine monohydrate at 0.1g/kg is able to significantly attenuate the chemotherapy-induced gain in fat mass over 16 weeks.
In a sample of people with colorectal cancer, to whom creatine supplementation was given for 8 weeks to assess its interactions with chemotherapy, creatine failed to benefit muscle function or quality of life. Benefit was seen in body cell mass and phase angle (indicative of cellular viability), but only in the subsample with less aggressive chemotherapy.
Creatine supplementation appears to have some minor protective effects on humans undergoing chemotherapy, where it has reduced fat gain from chemotherapy (leukemia) and has improved some biomarkers of cell viability
Several review studies assessing the safety of creatine supplementation tend to make note of increases in formaldehyde and possible carcinogenic results. Specifically, creatine is metabolized into an intermediate called methylamine, which can be converted to formaldehyde by the SSAO enzyme. An increase in urinary formaldehyde has been noted in youth given 21g of creatine for one week where both methylamine (820% increase) and formaldehyde (350%) were increased relative to control, but a more prolonged study using 300mg/kg (loading dose of around 20g) in adults for ten weeks failed to replicate these effects.
It has been thought that creatine metabolism can cause formaldehyde production, but this has failed to occur at an appreciable level during chronic intake, despite a transient increase with acute intake. This suggests adaptation
Anti-cancer effects have been observed with the creatine analogue cyclocreatine and have been replicated with creatine itself. These effects tend to be a reduction in which the rate of implanted tumors progresses. It is suspected that these observed effects (inhibition of growth, or attenuation of the rate of growth) are not due to the bioenergetic effect of creatine, secondary to creatine kinase, and these anti-cancer effects do not have a known reliability as the expression of creatine kinase varies widely based on the type of tumor. However, some studies suggest an inverse relationship between tumor progression in mice and concentrations of creatine in cells, with creatine depletion coinciding with tumor development.
The anti-cancer effects of creatine suggest it being an anti-tumor agent, as well as being negatively correlated with tumor production, with higher concentrations of creatine being associated with less tumor progression
In regards to genetic damage, creatine has been shown in vitro to reduce mitochondrial DNA damage, secondary to buffering stores of ATP. ATP depletion preceded genetic damage to mitochondrial DNA. This reduction of oxidative DNA damage has been noted in vivo following a short loading period in exercising people.
It has also been noted that supplementing creatine (which reduces internal synthesis of creatine and methylation requirements) preserved folate and tetrahydrofolate status (42% and 23%), which acted to preserve methyl groups for other processes. Despite this, global DNA methylation decreases 22% (assessed by the 5-methylcytosine/cytosine ratio) following creatine supplementation, usually seen as an anti-cancer effect in developed mammals. This study was unable to demonstrate why this reduction occured, and opposing effects have been noted in females with Rett syndrome, supplementing 200mg/kg creatine for 1 year, where global methylation increased secondary to preserving other methyl donors.
Creatine appears to reduce oxidative damage to DNA, but has unclear effects on DNA methylation. Practical significance of these mechanisms in regards to cancer prevention is not clear at this time
Creatine supplementation appears to augment the anti-cancer effects of Vitamin C and Methylglyoxal, a metabolic by-product of glycolysis. Methylglycoxal appears to inhibit step 1 of the electron transport chain in isolated mitochondria and cancerous mitochondria, but has not been implicated in doing so in normal tissue, as protective measures in normal cells appear to exist.
Creatine may by synergistic with methylglycoxal
Creatine is known to be present in the retina due to the expression of creatine kinase (CK) and the GAMT enzyme of creatine synthesis, which is also present in the mammalian retina. Creatine in the blood can be transported into the retina via the creatine transporter (confirmed in humans), and inhibiting transporter activity (by depleting the medium of chloride and sodium) reduces uptake by 80%. The fact that not all uptake was inhibited suggests that another transporter, such as the monocarboxylate transporter MCT12 (or SLC16A12), plays a role, perhaps moreso in the lens, where its levels were comparable to that of the major creatine transporter SLC6A8.
Creatine is known to occur in high levels of concentration in chicken photoreceptors, relative to other parts of the eye (10-15mM) alongside high levels of creatine kinase. The creatine transporter in human eyes also seems to be concentrated in the photoreceptors, which are known to be susceptable to hypoxic cellular death which, for humans, usually means retinal detachment.
The glial cells in the retina (Müller cells, known to supply photoreceptors with lactate for nutrition) do not appear to possess any creatine transporters although they appear to express AGAT, GAMT and can synthesize creatine for the retina. It is unknown if they have the capacity to donate creatine to photoreceptors.
Creatine kinase is expressed in eyes. The eyes can take creatine up from the blood via two different transporters, the classical SCL6A8 (creatine transporter) and MCT12. It seems that expression of the receptors and accumulation of creatine occur in a relatively higher level in photoreceptors (those that perceive color), and similar to many other tissues, they appear to protect the cells during periods of low oxygen availability
There is a genetic condition known as gyrate atrophy of the choroid and retina, which is associated with a high level of Ornithine in the blood and a relative decrease in Arginine, which causes a relative creatine deficiency due to L-arginine being required to make creatine and because high ornithine can suppress creatine synthesis (AGAT) in the glial cells of the retina. This condition can be attenuated by either reducting ornithine in the diet or by supplementing creatine which is, in this instance, therapeutic.
Elsewhere, it has been noted that in chronic progressive external ophthalmoplegia (CPEO; progressive weakening of the muscles around the eye and a mitochondrial disorder), there was a failure of creatine supplementation to benefit symptoms at 20g daily for four weeks. Creatine supplementation failed again at 150mg/kg for six weeks in people with either CPEO or another disorder associated with single gene deletions affecting the eyes (Kearns–Sayre syndrome; KSS) in improving muscular function.
Gyrate atrophy of the choroid and retinais a genetic condition, which causes high blood ornithine levels, and due to the suppression of AGAT by excessive blood ornithine levels, there are some retinal problems. Supplemental creatine appears to attenuate the negative effects by preventing a suppression of creatine synthesis
Epithelial cells taken from the respiratory tract (nasal, tracheal, and bronchial) express very low levels of creatine kinase and phosphocreatine, and addition of 15mM creatine to the medium does not appear to alter their growth or function.
The pancreas is one of the extrahepatic (beyond the liver) organs that can synthesize creatine, alongside the kidneys. Freshly prepared pancreatic β-cells will normally secrete insulin in response to glucose stimulation, and it appears that phosphocreatine is required, since phosphocreatine is increased in response to glucose alongside an increase in the ADP:ATP ratio. They appear to close ATP sensitive potassium channels (KATP channels), causing a release of insulin secondary to calcium release. Both phosphocreatine and ADP are implicated, but it seems that despite the channel being sensitive to ATP the concentration of ATP in a pancreatic cell (3-5mM) is already much above the activation threshold (in the micromolar range) and thus a further increase would not do anything appreciable.
Incubation of a β-cell with additional creatine (5-10mM), even at saturated concentrations of glucose, is able to further increase insulin secretion in response to glucose, specifically as the Leucine metabolite 2-ketoisocaproic acid, potassium, and a potassium channel blocker were all ineffective. This has been found to occur in rats given 2% of the diet as creatine but has since failed in humans given 5g of creatine.
Phosphocreatine is involved in mediating the insulin secretion in response to glucose, and it appears that additional creatine should exacerbate this response when looking at isolated pancreatic cells. When tested in humans, however, it has failed to augment insulin secretion in response to a meal
Creatine is mostly synthesized in the liver via AGAT and GAMT (the other locations are neurons, as well as the pancreas and kidneys) despite it not being stored in high levels in the liver like glycogen or adipose would be. Supplemental creatine is known to suppress AGAT by downregulating transcription, which probably occurs in humans (since the products of AGAT are reduced with creatine supplementation.
This suppression of creatine synthesis is thought to actually be beneficial, since creatine synthesis requires S-adenosylmethionine as a cofactor and may use up to 40-50% of SAMe for methylation (initially thought to be above 70%, but this has since been re-evaluated), but the expected preservation of SAMe may not occur with supplementation. Reduced creatine synthesis, via preserving methyl groups and Trimethylglycine (which would normally be used up to synthesize SAMe), is also thought to suppress homocysteine levels in serum, but this may also not occur to a practical level following supplementation.
Creatine is mostly synthesized in the liver, and supplementation of creatine will suppress subsequent production of creatine in the body (since high levels of creatine will suppress its own synthesis) by downregulating the enzymes of synthesis. This is a reversible suppression
In regards to liver fat buildup (steatosis), which is normally associated with reduced availability of S-Adenosyl Methionine and a suppression in expression of genes involved in fatty acid oxidation (PPARα and CPT1), creatine supplementation at 1% of the rat diet, alongside a diet that induces fatty liver, is able to fully prevent (and nonsignificantly reduce relative to the control given standard diets) the aforementioned changes and the state of steatosis, as well as changes in serum biomarkers (glucose and insulin) that accompany steatosis.
These protective effects are similar to those seen with Trimethylglycine, since they both caused an increase in liver concentrations of Phosphatidylcholine (PC; causing an increase in vLDL production and efflux of triglycerides from the liver), and both TMG and creatine are thought to work indirectly by preserving SAMe concentrations, since PC synthesis requires SAMe as well (via PEMT) and genes involved in fatty acid metabolism in the liver that were not affected by the diet (VLCAD and CD36) were unaffected by creatine.
Creatine supplementation appears to be somewhat similar to TMG supplementation in the sense that they both promote localized synthesis of phosphatidylcholine, effluxing triglycerides from the liver into serum and thus potently protecting from diet-induced fatty liver. The concentration in which this occurs is within the range supplemented in humans
In rats, beginning an exercise program is known to increase serum levels of some liver enzymes (ALT and GGT) while supplementation of high levels of creatine, at 4% of the diet over 60 days does not modify this.
When examining human studies, young adult athletes who reported creatine usage for over two years prior to the study (retrospective design) were not significantly different than controls. Elsewhere, in a similar cohort of athletes reporting creatine usage for up to four years, failed to note significant differences in liver enzymes, although a nonsignificant reduction in LDH was noted.
Minor liver lesions (grade I, no grade II or III; pathology not indicative of toxicity) have been in SOD1 G93A transgenic mice (a research model for amyotrophic lateral sclerosis or ALS, but used in this study to assess a state of chronic pro-oxidative stress) for 159 days with 2% of feed intake and in CD-1 rats (seen as normal) over 56 days with 0.025-0.5mg/kg in CD-1 mice, although in Sprague-Dawley rats (normal controls) there were no significant differences noted even after 2% of feed intake for 365 days. These observations appear to be due to the strain or the rodents used, and human studies on ALS (what the SOD1 G93A transgenic mice are thought to represent) extending from nine months to sixteen with up to 10g of creatine daily have failed to find any abnormalities in serum biomarkers of liver or kidney health with supplementation of creatine.
There appear to be species-related responses to creatine supplementation in rat livers, where some strains experience non-pathological lesions (minor, but indicative of hepatitis). These do not appear to influence all strains, and the human condition it is thought to mimick (ALS) does not appear to be negatively affected
The kidneys are known to express a secondary creatine transporter known as the monocarboxylate transporter 12 (MCT12; also known as SLC16A12) similar to the retina, and due to rats lacking this transporter having higher urinary creatine levels, it is thought to play a role in re-uptake.
In otherwise normal animals, supplementation of creatine at 0.2% of the rat diet over 10 weeks appeared to reduce glomerular filtration rate and renal blood flow (no alterations in urinary protein) in rats at rest, but this reduction was not present in those subject to exercise.
In regards to rodent models with nephrectomy (partial removal of kidneys), nephrectomized rats may have significantly reduced creatine synthesis rates via impairment of methylation (the GAMT enzyme) although creatine reuptake from the urine seems unimpaired. Supplemental creatine in a rat model of 2/3rds nephrectomy (2% creatine in the diet) does not appear to negatively influence kidney function as assessed by the serum biomarkers of cystatin C, and urinary protein or creatinine clearance rates. Elsewhere, 2% of the diet in rats for two weeks, again failed to show negative effects on kidney function (and showed benefit in reducing homocysteine in late-stage uremic rats) and while there is not much human evidence for the rat nephrectomy model, a lone case study in a man with a single kidney failed to find an impairing effect of creatine (20g daily for five days and 5g for another month) in conjunction with a high protein diet.
In Han:SPRD‐cy rats (human polycystic kidney disease model) there is pre-existing renal damage, which is accelerated upon ingestion of creatine supplementation at 0.3% of the diet for five days and 0.03-0.05% for the next 35 days (equivalent to human loading and maintenance). It is known that, during this particular disease state, that renal water content and size progressively increases and since creatine supplementation furthered the increase by an additional 2.1%, it was thought that this property of creatine explained the 23% increased cyst scores seen relative to control.
There are mixed rodent reports on pre-existing kidney damage seen with creatine supplementation, and the rat genetic model intended to reflect human polycystic kidney disease has been associated with an increased rate of kidney damage. Nephrectomy (removal of portions of the kidney) does not appear to have any effect
When looking specifically at human studies, there has been a failure of creatine supplementation to induce or exacerbate kidney damage in people with ALS, who do not experience kidney damage for up to or over a year's worth of supplementation in the 5-10g range. Postmenopausal women, type II diabetics, persons on hemodialysis, otherwise healthy elderly or young individuals and athletes do not experience kidney damage either.
Most, if not all, populations of humans studies with creatine supplemenation have failed to find any significant damage to the kidneys as assessed by non-creatinine biomarkers (blood urea or urinary proteins) or the rate of glomerular filtration
Creatine is known to increase its concentration in the placenta and brain normally during the midgestation phase until term, with further increases in the brain for another two weeks after birth; this appeared to be due to the fetus itself express the creatine enzymes of synthesis (AGAT and GAMT) after 5% of the gestation time is passed (0.9 days in spiny mice) and despite creatine normally suppressing AGAT when supplemented or at high concentrations it appears that maternal supplementation of the diet with 5% creatine from the half-way mark of pregnancy until term does not alter creatine synthesis in the newborn (no alterations in either AGAT or GAMT) nor does it affect the creatine transporter.
Supplementation of creatine by the mother is known to increase creatine content of the placenta (105% above control) and some tissues of the fetus such as the brain (3.6%), heart (14%), kidney (22%), and liver (37%) with a diet that contained 5% creatine from the half-way point of pregnancy onward.
When the mother (rodent, no human studies) supplements creatine, the creatine can reach the fetus and is thought to confer protective and growth enhancing effects. Supplementation of creatine does not impair creatine synthesis in the fetus when ingested in the latter half of pregnancy
Injections of creatine are known to be neuroprotective against low oxygen levels (hypoxia) even to neonatal rats thought to be associated with increasing the pool of phosphocreatine and creatine collectively; since oral ingestion of creatine by the mother increases brain concentrations of creatine by 3.6% in the fetus prior to birth it is thought to be protective in the fetus when they are subject to hypoxic (low oxygen) stressors such as a caesarean section.
It appears that when creatine is increased in the fetus (from maternal supplementation of 5% creatine) that the fetus has a greater chance of survival and increased growth rates to a level not significantly different than vaginal birth. Protection has also been noted in the offspring's diaphragm from the damage of hypoxia by preserving muscle fiber size, the kidneys, and neural tissue itself has been noted to be protected (due to less oxidation in the brain and less cellular apoptosis).
It appears that maternal supplementation of creatine from the midpoint of pregnancy until term, at least in rodents, is able to protect the fetus from damages associated with low oxygen (ie. caesarean section)
Skin degradation and loss of integrity is due to a loss of collagen and degradation of the extracellular matrix which is enhanced by UV radiation (produces reactive oxygen species which stimulate MMPs) and contributes to skin integrity loss and wrinkling; due to the stimulation of collagen being associated with a cellular surplus of energy and intracellular stores of energy declining with age creatine has been investigated as a topical anti-aging agent. In vitro, creatine appears to be rapidly absorbed through the skin (52% within an hour, remaining similar at 3 hours) with most creatine found in the stratum corneum (79.6-86.5%) follwed by the epidermis (9-13.2%) and dermis (4.5-7.1%) and is successful in stimulating collagen expression and procollagen secretion in fibroblasts, with the latter increasing to 449+/-204% of control.
The increased cellular storage of creatine may also confer antioxidative effects secondary to enhancing mitochondrial function and may play a preventative role in addition to rehabilitative.
A study using creatine at 0.02% of a face cream (confounded with 8% glycerol and 0.4% Guarana) was able to exert a skin tightening effect over 6 weeks, reducing wrinkles and jowl volume. Combination therapy has also been used with creatine and folic acid (both in vitro and in vivo resulting in increased skin firmness and reduced coarse and fine wrinkles)
Creatine may play a role in topical anti-aging skin products at around 0.02% of the cream, and theoretically can enhance the effects of other agents by providing more energy for a skin cell to use. Creatine may inhernetly have a pro-collagen effect, reduce wrinkle formation, and improve skin integrity
Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig's Diseases) is the most common motor neuron disease with major complications involving muscular weakness and lack of muscle control, and in advanced cases of ALS the main cause of death appears to be respiratory failure due to not being able to control the intercostal muscles.
The first published results (not blinded) noted that a loading phase of 20g for a week followed by 3g daily for up to six months was able to enhance maximal voluntary isometric muscular contraction (MVIC) on a dynamometer for both the knee and elbow joints, with enhanced fatigue resistance on the same joints in more than half of subjects (53-70% response rate).
Some studies have failed to find improvements in MVIC (in regards to attenuating the decline over time) with 10g daily over 16 months, with 5g daily (after a five day loading phase) for six months, and 5g daily over nine months.
The shortest and most preliminary study noted that, over the short term, creatine delivers on its expected improvement in physical strength. However, longer studies that measure the rate of loss for muscle function (deterioration of muscular capacity that is known to occur with ALS) have repeatedly failed to find a benefit with creatine supplementation
One study lasting 16 months and used alongside the pharmaceutical riluzole with creatine supplementation at 10g daily noted that, after 34 of the patients died from ALS, that creatine failed to exert protective effects against ALS-related mortality (adjusted hazard ratio of 0.78 with a 95% CI of 0.47–1.48) and a smaller study measuring only eight deaths noted that the six in placebo (relative to two in creatine) was too small to detect a statistically significant difference, and a nonsignificant trend to increase survival has been noted elsewhere with 5g of creatine daily with a similar ratio (3 deaths in placebo to one death in creatine).
The first open label trial on ALS failed to significantly alter lung function as assessed by FEV (when comparing the rate of decline pretreatment relative to treatment) and creatine has elsewhere failed to benefit lung function at 5g daily for months relative to control and failed to significantly attenuate the rate of lung function deterioration over 16 months at 10g daily and 5g daily over nine months.
Parameters of lung function (main cause of death in ALS is declining respiratory function) have failed to find benefit with creatine, and when quality of life is measured, there is no benefit. That being said, despite one study failing to find any significant differences in mortality risk, two other studies have suggested that creatine may reduce the risk. The results were nonsignificant, but due to all treatments being well tolerated it is thought that creatine may still play a role as an adjuvant
Mitochondrial myopathies are a subgroup of mitochondrial cytopathies of which the skeletal muscle is negatively influenced, and are characterized by weaknesses in muscular function and energy metabolism. These particular myopathies are thought to have benefit with creatine supplementation due to aiding some of the dysregulated energy production.
A loading phase of 10g creatine monohydrate for two weeks and 4g for the final week in subjects with MELAS (Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like episodes) has been noted to increase physical strength relative to baseline, although the poor VO2 max seen in these subjects was not affected, and a case study exists where a patient with a relatively novel mutation in their mitochondrial function (affecting cytochrome B) found benefit with creatine at 10g daily and another case of MELAS which found both cognitive and physical benefits with 5g creatine supplementation whereas four controlled case studies of 100-200mg/kg daily in children with myopathies found improved muscular endurance (30-57%) and muscular power (8-17%) after 100-200mg/kg daily for at least three months.
Studies investigating patients with mixed mitochondrial myopathies who have reported creatine usage (not controlled trials) have noted benefits such as 12% improvement in steady-state cycling performance with doses in the range of 100-350mg/kg.
When examinng mitochondrial myopathies, creatine does not have overly robust (strong) evidence for the treatment of these disorders, but it seems to benefit pretty much all patients in improving physical performance and quality of life
Duchenne's Muscular Dystrophy (DMD) is known to be associated with a reduction in intracellular creatine stores known to only affects males; it is an X-linked progressive myopathy associated with abnormalities in the dystrophin gene. The standard therapy at this moment in time are corticosteroids such as prednisone, and creatine is thought to be therapeutic since the known targetable abnormalities in Duchenne's Muscular Dystrophy (impairment in protein synthesis associated with oxidative stress and increased protein breakdown) is a property of creatine and supplementation showed promise in the first case study and benefit in a group of mixed dystrophinopathies.
100mg/kg creatine monohydrate daily over four months in boys with DMD is able to enhance handgrip strength in the dominant hand only (less than 10% increase) and increase whole-body lean mass, while the trend towards whole body strength reduction seen in placebo was ablated and there was no interaction with corticosteroids; this study failed to find an influence on activities of daily living or lung function. Elsewhere in children not on corticosteroids with DMD, supplementation of 5g creatine for eight weeks was confirmed to increase muscular phosphocreatine content and according to a manual muscle test (MMT) there was a significant improvement in muscular function relative to placebo with more parents reporting benefit with creatine (53.8%) relative to placebo (14%).
There appear to be mild therapeutic benefits with low doses of creatine supplementation in children with Duchenne's Muscular Dystrophy, as power output and parent-rated symptoms are both improved relative to placebo
Myotonic Dystrophy type I (DM1) is an inhereted muscular disorder, which is due to an expanded CTG repeat in the DMPK gene on chromosome 19q13.3 (genetic cause of the disorder) resulting in muscular degeneration and myotonia. The related myopathy, myotonic dystrophy type II (DM2) which is also known as proximal myotonic myopathy (PROMM) is due to a CCTG repeat on 3q, and are less affected by myotonia and more by muscular pain and weakness. There is no cure for either due to them being genetic disorders, and current therapies are aimed at reducing side-effects such as Modafinil for the somnolence and perhaps creatine for the reductions in strength and functionality.
Creatine is thought to be therapeutic due to a pilot study on an assortment of neuromuscular diseases (91 patients in total; 15 of which had congenital myotonias) where there was an overall increase in strength.
Myotonic Dystrophy is a genetic disorder resulting in physical frailty, somnolence, and reduced physical functioning in everyday life
In patients with DM1 given a short loading phase (10.6g for ten days) followed by a 5.3g maintenance for the remainder of an 8-week trial noted that supplementation noted a minor improvement in strength (statistical significance only occurred since placebo deteriorated) and no significant difference was noted in self-reported perceived benefits. Maintaining a 5g dosage for four months has also failed to significantly improve physical performance (handgrip strength and functional tests) in those with DM1, possible related to a failure to increase muscular phosphocreatine concentrations.
Elsewhere, a pilot study in persons who met the diagnostic criteria for myotonic dystrophy type 2 (DM2 or PROMM) given 10g of creatine daily for three months failed to find an increase in strength, but there appeared to be a significant improvement in subjective well being reported by the patients relative to placebo.
The failure of creatine to improve physical performance in these conditions is thought to be related to the myopathies in general, which are known to have less phosphocreatine in skeletal muscle associated with reduced expression of the creatine transporter; as creatine has once been noted to not accumulate in the skeletal muscle of persons with DM1 given supplementation it is thought the subjects do not respond to therapy.
Creatine supplementation has once been noted to improve well being and fatigue resistance in persons with DM2, but has twice failed in those with DM1. In all three studies it has failed to improve power output, and this is thought to be due to a reduction in the expression of the creatine transporter preventing an increase in muscular phosphocreatine content
McArdle's Disease is a myopathic disorder associated with fatigue and contractile dysfunction, due to alterations in the release of glucose from glycogen (via defects in myophosphorylase enzyme function) resulting in an inability to conduct high intensity work as easily. Creatine is thought to be therapeutic because, beyond the general strength enhancing properties of creatine, persons with McArdle's Disease have an upregulation of phosphofructokinase (PFK) enzyme activity and increasing phosphocreatine storages suppresses the activity of this enzyme
One pilot study using 150mg/kg creatine monohydrate for a five day loading phase followed by maintenance (60mg/kg) for the remainder of the five weeks noted that supplementation was associated with less muscle symptoms and complaints alongside improved muscular function yet a later trial trying to replicate the obsevations using 150mg/kg daily for five weeks noted the opposite, that creatine supplementation exacerbated symptoms.
It was hypothesized that this negative effect could be due to proton uptake from phosphocreatine degradation, since persons with McArdle's disease may have impairments in regulating intracellular acidosis.
McArdle's Disease is a myopathy associated with impaired glucose release from glycogen, and thus impairments in muscle function at times when glucose would be the primary energy substrate. Creatine is thought to be therapeutic, and has shown differing effects in the two trials so far (benefit and worsening of symptoms) for currently unknown reasons
Creatine has been shown before in vitro to protect from MPTP induced toxicity, which targets dopaminergic neurons in the substantial nigra and induce Parkinson's Disease in research animals and also protected these cells from death induced by low oxygen or glucose. One study noted that dopaminergic cell survival under the influence of creatine was 1.32-fold higher than control cells, and the soma (cell body) was enlarged by 1.12-fold in these cells, and creatine showed some growth-enhancing effects as well as reducing destruction of dopaminergic neurons by various insults.
Creatine supplementation is being explored as a treatment for sarcopenia, the passive loss of lean mass that occurs with aging. The effects of creatine on alleviating sarcopenia seem to be more significant when paired with resistance training. Creatine is also being researched as a method for slowing cachexia and wasting syndromes.
In a study using lifelong creatine supplementation in SAMP8 mice (a model used to research aging), no significant preventative effect was found on sarcopenia rates at 2% dietary intake
Preliminary evidence for the usage of creatine in order to prevent sarcopenia has not been promising, as rodent research has failed to find a protective effect
In a pilot study on youth with cystic fibrosis, supplementation of creatine at 12g for a week and 6g for eleven weeks afterwards was associated with a time-dependent increase in maximal isometric strength reaching 14.3% which was maintained after 12-24 weeks of supplement cessation (18.2% higher than baseline). This study noted that more patients reported an increase in well being (9 subjects; 50%) rather than a decrease (3; 17%) or nothing (6; 33%) and that there was no influence on chest or lung symptoms.
Creatine appears to increase wellbeing (quality of life) and physical strength in youth with cystic fibrosis, but it does not appear to confer benefit to the primary chest and lung symptoms
In persons with COPD given either glucose placebo (40.7g) or creatine supplementation (5.7g creatine with 35g glucose) thrice daily for two weeks followed by a single dose for ten weeks, supplementation was associated with improvements in muscular strength and endurance but not cardiovascular exercise potential. A later trial of larger power using a loading phase of 22g creatine with a maintenance phase of 3.76g during rehabilitative exercise failed to replicate the improvements in skeletal muscle performance despite increased body weight seen with creatine, and the failure to improve cardiovascular performance during aerobic exercise seen in both aforementioned studies has been replicated elsewhere after eight weeks supplementation, where muscular performance was again unaffected.
Creatine supplementation has been noted to improve general well being and health status (assessed by St George’s Respiratory questionnaire) of persons with COPD over two weeks loading (17.1g daily with carbohydrates) and ten weeks of 5.7g maintenance. The studies that failed to find improvements with creatine supplementation on muscular performance also failed to find improvements in this rating scale relative to placebo.
Due to its antidepressive properties, creatine supplementation has been investigated in persons with bipolar disorder at times (despite creatine levels in the brains of bipolar patients not being significantly different than controls, although the activity of creatine kinase seems to reflect the state of manic or depressive symptoms).
One open-label study in resistant depression where 10 depressive patients (two of which had bipolar disorder) were given 3-5g creatine daily for four weeks found that, in both of these patients, that hypomania/mania developed associated with creatine supplementation.
While there is no controlled evidence for the effects of creatine on bipolar symptoms, the lone pilot study suggested that supplementation could be causative of hypomanic symptoms in bipolar persons
Insulin secretion seems to have interplay with creatine supplementation, however this is only clinically significant during the first few days of loading when myocyte stores of creatine are depleted. The effect is mediated through high level of insulin release and it appears to be independent of the creatine transporter.
During a creatine loading phase, it is possible for insulin secretion to enhance the rate of uptake into myocytes. When the myocytes are saturated with creatine (seen after 3 days of loading), then this insulin effect seems to disappear.
In vitro studies on endothelial cells have noted that the benefits of creatine against atherosclerosis (via immune cell adhesion to the endothelial cell) are blocked with the pharmaceutical ZM241385, a high affintiy adenosine A2A receptor antagonist; this particular receptor subset (A2A rather than other adenosine receptors) and its inhibition are similar to Caffeine, suggesting that caffeine may have an inhibitory effect on this mechanism of creatine.
Although the anti-atherosclerotic properties of creatine are not well studied at this point in time, they appear to be dependent on the A2A receptor (caffeine's target) not being inhibited
Co-ingesting creatine with Caffeine appears to partially negate the benefits of creatine supplementation (at 5mg/kg bodyweight) during the loading phase. The exact mechanism is not known, but might be related to opposing actions on muscle contraction time.
However, caffeine does not negate the benefits of creatine loading when not coingested, but just taken before exercise in the same dosage. This result indicates that loading creatine without caffeine on a daily basis, but saving caffeine for select workouts, may be an effective strategy as creatine does not adversely affect Caffeine's ergogenic effects and may enhance creatine's effectiveness in anaerobic exertion if the two compounds are alternated.
The effects of creatine and caffeine coingestion when it comes to human interventions on physical performance are not yet clear
The combination of creatine and β-alanine appears to augment prolonged (4 week) beneficial changes in body composition (more muscle, less fat) relative to creatine alone.
Trimethylglycine (TMG; betaine) is a dietary supplement and component of Beet Root which is known as a methyl donor, contributing to metabolic processes in the body which require a methyl group either directly (the methylation of homocysteine) or indirectly via replenishing the active form of folate or via replenishing S-Adenosyl Methionine (SAMe). As the synthesis of creatine (via GAMT) requires a donation from SAMe, it is thought that TMG can aid in creatine synthesis (which has been noted in the rat liver in the absence of creatine supplementation).
The one study to investigate this claim noted that the addition of 2g of supplemental TMG to 20g supplemental creatine failed to outperform creatine by itself in increasing muscular creatine stores or power output.
Although TMG is indirectly involved in the synthesis of creatine, the evidence at this point in time does not support an additive nor synergistic role of TMG supplementation alongside creatine
In a study with Alpha-Lipoic Acid, 1,000mg of ALA paired with 100g sucrose and 20g creatine monohydrate was more effective in increasing muscular creatine levels relative to creatine alone and creatine combined with sucrose. This apparent augmentation of creatine uptake into muscle cells was used alongside a loading period. Another study investigating a nutrient mixture (150g glucose, 20g creatine, 2g/kg bodyweight glycerol) on heat tolerance in trained athletes found that replacing one third (50g) of the glucose with 1g ALA resulted in no significant differences between groups (in regards to heat tolerance and cardiovascular performance) despite the reduction of 50g carbohydrate.
A study in swine noted increased water retention (via a PY value) in the group fed both creatine and alpha-lipoic acid at a dose of 24g and 600mg daily; respectively.
COX-2, a pro-inflammatory enzyme, is sometimes a therapeutic target for both muscle soreness and some degenerative diseases that are exacerbated by inflammation. COX-2 inhibitors (in this study, rofecoxib) and creatine monohydrate both appear to protect dopaminergic neurons from being destroyed by toxins, and can protect in an additive manner; suggesting possible usage of both to reduce the risk of Parkinson's Disease.
There are no clinically significant side-effects of creatine supplementation acutely. Numerous trials have been conducted in humans with varying dosages, and the side-effects have been limited to gastrointestinal distress (from too much creatine consumption at once) and cramping (from insufficient hydration).
A dose of 5g daily has strong evidence for not causing any adverse side effects and 10g has been used daily for 310 days in older adults (aged 57+/-11.1) with no significant differences from placebo. Such a dose has also been demonstrated for long-term safety in Parkinson's Disease, and at least one small retrospective study in athletes (surverying persons taking creatine for up to or over a year) failed to find any significant differences in a battery of serum health parameters. Other studies measuring serum parameters also fail to find abnormalities outside the normal range.
Studies that use a dosage range typical of creatine supplementation (in the range of 5g a day following an acute loading period) note increases to total body water of 6.2% (3.74lbs) over 9 weeks, 1.1kg over 42 days,. Interestingly, some studies comparing creatine paired with training against training itself fail to find a significant difference in percentage of water gained (which is inherently to activity) with standard oral doses of creatine (although low dose creatine supplementation of 0.03g/kg or 2.3g daily doesn't appear to increase water retention) despite more overall water weight being gained; due to an equal gain of dry mass in muscles. One study has quantified the percentage increase in mass of muscle cells to be 55% water, suggesting they are fairly equal.
In regards to the loading period, two reviews suggest that the range of weight gain associated with creatine supplementation at 20g for 7 days is in the range of 0.9-1.8kg (1.98-3.96lbs). The highest reported increase in water weight associated with creatine loading, although measured a month after loading started (after a maintenance phase) was 3.8kg (8.36lbs).
Studies measuring extracellular water versus intracellular water note similar increases in both associated with creatine, and creatine does not tend to disturb the ratios of water to dry mass in various tissues measured. At least one study in older men (48-72yrs) has failed to find a significant difference in both intracellular and extracellular water concentration after 14 weeks of 5g daily (with gatorade) relative to gatorade in isolation; the ratio being maintained.
One case study exists in a man with focal segmental glomerulosclerosis who experienced an accelerated rate of GFR decline during supplementation (5g thrice daily for loading, then a 2g maintenance for seven weeks) which was partially reversed upon supplement cessation; this was deemed strong circumstantial evidence, and the brand was not named. Elsewhere, interstitial nephritis has been reported in a man associated with creatine supplementation although symptoms arose four weeks after supplementation started (no evidence to support correlation) and some studies involving athletes and various dietary supplements have attempted to draw a correlation with creatine and cases of rhabdomyolysis. Finally, one study in a diabetic person ingesting both metformin and creatine resulting in metabolic acidosis has attempted to place causation on creatine but did not establish causation nor circumstantial evidence.
There are numerous case studies on the interactions of creatine and possible negative effects on the liver, but with the exception of Pritchard and Kalra (study on glomerulosclerosis) all other case studies have failed to provide the minimal evidence to suggest a good relationship between creatine and the observed effects
One case study exists where a man with a single kidney with some damage to it (low GFR) supplemented creatine at 20g for a period of five days and then a maintenance period for 30 days failed to cause any kidney damage, despite having a diet very high in protein (2.8g/kg).
One case study suggested that a single impaired kidney is not negatively affected by creatine supplementation at the standard loading and maintenance dosage when monitored for just over a month
Creatine is normally metabolized into creatinine (note the difference in spelling), which is eliminated by the kidneys under normal conditions. When the kidneys fail and they cannot clear the blood as effectively many metabolites get 'backlogged' in the blood so to speak, and creatinine is easy to measure and as such it is a biomarker of kidney damage; this means that if creatinine is elevated, the doctor may suspect some kidney damage. Low dose creatine may not cause alterations in this biomarker in otherwise normal adults but high doses of supplemental creatine may cause a false positive (an increase in creatinine, due to creatine turning into creatinine, that does not signify kidney damage) and is seen as a diagnostic error.
Kidney damage (from anything) will cause high blood creatinine levels, and creatine can also increase blood creatinine levels in a manner that is not due to damaging the kidneys. This results in a false positive when trying to diagnose kidney damange when the subject also supplements with creatine, and does not signify any actual damage to the kidneys
(Common misspellings for Creatine include Creatin, Craetine, creating, creetine, createen)
(Common phrases used by users for this page include muscle mass examine.com, kreatine esther acryl, is HgH better than creatine for muscle mass, how fast does creatine degrade in water, creatine supplements scientific, can creatine cause testicular cancer)